Potential mechanisms of natural metabolites and botanical drugs foumulae for the treatment of non-alcoholic fatty liver disease: targeting the gut microbiota to modulate the immune system

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder worldwide and is also a significant risk factor for triggering non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and liver cirrhosis. Disorders in the hepatic immune system constitute one of the key drivers of NAFLD progression; thus, targeting immune dysregulation may represent an effective strategy to delay or reverse NAFLD advancement. Meanwhile, gut microbiota (GM) and its metabolites directly influence liver immune responses throughthe “Gut-Liver Axis.” Dysbiosis of the GM triggers damage to the intestinal mucosal barrier. Subsequently, substantial bacterial metabolites derived from GM can induce overactivation of the hepatic immune response, thereby driving NAFLD progression. Thus, targeted intervention in the GM-immune response axis represents an effective therapeutic approach against NAFLD advancement. Numerous current studies indicate that botanical drugs and their metabolites can counteract NAFLD progression by intervening in GM and its metabolites to regulate hepatic immune imbalance. This article reviews the roles of immune cells, GM, and their metabolites in NAFLD development, while exploring the targets and/or pathways through which botanical drugs and their metabolites modulate GM and hepatic immune responses. This aims to provide a foundation for utilizing botanical drugs as natural adjuvants to address immune dysregulation during NAFLD treatment.

1 Introduction

NAFLD is a highly prevalent chronic progressive liver disease (Diehl and Day, 2017). It typically begins as simple hepatic steatosis, which can progress to NASH, liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). Immune responses not only determine the progression from NAFLD to NASH/liver fibrosis (Deng et al., 2022), but the retention and recruitment of immune cells within the liver also activate hepatic stellate cells (HSCs), thereby driving the development of cirrhosis and even HCC (Loomba et al., 2021). Therefore, modulating immune responses represents a promising strategy for mitigating NAFLD progression (Martínez-Chantar et al., 2021). On the other hand, there exists extensive crosstalk between the gut and the liver, which is referred to as the “gut–liver axis” (Tilg et al., 2022). The anatomical and functional connections between the gut and the liver make this axis a crucial pathway for bidirectional communication between the GM and the liver (Wang R. et al., 2021). As shown in Figure 1. A balanced GM and intestinal barrier integrity are essential not only for maintaining the homeostasis of the gut–liver axis (Schnabl, 2013), but also for ensuring hepatic immune stability in the host (Wang J. et al., 2023). Disruption of intestinal homeostasis can alter the immune status of the liver. Dysbiosis of the GM can compromise the intestinal mucosal barrier. Microbial components may enter the systemic circulation via a impaired intestinal barrier in the form of extracellular vesicles (EVs), and bind to pathogen recognition receptors (PRRs) in the liver as pathogen-associated molecular patterns (PAMPs) (Wang R. et al., 2021). This interaction leads to overactivation of immune cells, exacerbation of hepatic inflammation, and stimulation of HSCs, thereby promoting the development of liver fibrosis (Vajro et al., 2013). Additionally, metabolites derived from GM can act as damage-associated molecular patterns (DAMPs) by binding to PRRs on the surface of liver cells such as Kupffer cells (KCs), liver sinusoidal endothelial cells (LSECs), and cholangiocytes, thereby inducing hepatic immune responses and aggravating inflammatory liver injury (Wang R. et al., 2021). Thus, the GM can modulate liver immunity via the gut–liver axis, thereby influencing the progression of NAFLD.

FIGURE 1

The pathological mechanism of NAFLD is highly complex, making single-target therapies largely ineffective. To date, only Resmetirom has been approved for treating NASH patients with moderate hepatic fibrosis (F2∼F3 stages). Botanical drugs—natural resources containing multiple bioactive compounds—possess broad pharmacological actions, low toxicity, and high safety profiles, demonstrating excellent potential for treating chronic progressive diseases. Currently, botanical drugs have emerged as significant clinical agents (Hu et al., 2023), attracting considerable research attention. A growing body of studies (Che et al., 2022; Zhu et al., 2023) confirms that botanical drugs can repair damaged intestinal barriers, promote structural remodeling of GM beneficial to host health, alter the production of GM metabolites, and consequently regulate hepatic immune responses. Furthermore, botanical drugs modulate autophagy to promote apoptosis (Niazpour and Meshkani, 2025), inhibit HSC activation and hepatocyte apoptosis to counteract hepatic fibrosis (Wang et al., 2024b), and activate SIRT1 to reduce lipid accumulation and ferroptosis (Liu Y. et al., 2025), and other mechanisms to inhibit NAFLD progression. This also reveals a novel therapeutic strategy for NAFLD. Building upon this foundation, this review synthesizes current research on botanical drugs intervening in NAFLD development through the GM-liver immune axis, thereby providing theoretical support and clinical references for future botanical drug-based NAFLD interventions.

2 Immune cells and NAFLD

As one of the core organs for immune regulation, the liver harbors abundant immune cells that participate in immune responses (Peiseler et al., 2022). Under immune homeostasis, immune cells disperse throughout the liver to expel toxic substances while phagocytosing and eliminating pathogens (Bogdanos et al., 2013). Translocation of gut-derived immune signals to extraintestinal sites triggers hyperactivation of the immune system (Powell et al., 2021), promoting KCs activation in the liver and recruitment of circulatory macrophages to hepatic tissue (Golabi et al., 2019), thereby intensifying the accumulation and infiltration of inflammatory factors within hepatocytes (Nati et al., 2016). Persistent hepatic inflammation not only induces hepatocyte injury and necrosis, driving NAFLD progression to NASH, but also activates HSCs to accelerate hepatic fibrosis, cirrhosis, and HCC (Kechagias et al., 2020). Research (Huby and Gautier, 2022) has established that NAFLD progression is closely associated with macrophages, neutrophils, dendritic cells (DCs), and natural killer T lymphocytes (NKTs). As shown in Figure 2.

FIGURE 2

These immune cells synergistically interact through complex networks of cytokines and chemokines, forming an inflammatory cascade. During the progression of NAFLD from early simple fat accumulation to inflammation, fibrosis, and ultimately cirrhosis, the roles of various immune cells exhibit significant stage-dependent changes. In the early stage of fatty liver, excessive lipid deposition in hepatocytes triggers macrophages to initiate inflammation. During the hepatitis phase, macrophages serve as inflammation amplifiers, neutrophils act as executors of early liver injury, while T cells, DCs, and NKT cells participate in amplifying the inflammatory cascade. During the fibrotic stage, macrophages and NKT cells serve as pivotal pro-fibrotic drivers. In the cirrhosis phase, DCs and T cells sustain chronic immune activation while neutrophils persistently promote inflammation, collectively maintaining chronic low-grade inflammatory responses (Huby and Gautier, 2022).

2.1 Macrophages

Hepatic macrophages can be categorized into resident KCs (Res-KCs) and monocyte-derived macrophages (MDMs) based on their cellular origins (Guilliams and Scott, 2022). Lipotoxicity suppresses self-renewal of Res-KCs and induces their apoptosis (Tran et al., 2020; Daemen et al., 2021), thereby inducing monocyte recruitment to the liver and their differentiation into MDMs to replenish the macrophage pool (Guilliams and Scott, 2022). Res-KCs promote liver regeneration by clearing cellular debris and extracellular matrix (Crespo et al., 2023); whereas MDMs typically exhibit high expression of inflammation-related genes, exacerbating liver injury (Tran et al., 2020). Notably, TREM2 expressed in MDMs can reverse their pro-fibrotic function, exerting protective effects through facilitating the clearance of apoptotic hepatocytes and reducing inflammatory factor production (Wang X. et al., 2023). Based on inflammatory phenotypes, macrophages are classified into M1 and M2 subtypes. M1 macrophages drive fibrosis progression by secreting IL-6, TNF-α, various interleukins, and chemokines (CXCL9–11, CCL15/20) (Trinchieri, 2003; Mantovani et al., 2004; Martinez et al., 2006). Conversely, M2 macrophages exert anti-inflammatory effects by expressing TGF-β and IL-10, thereby inhibiting NAFLD progression (Hesse et al., 2001). Studies demonstrate that depleting KCs and MDMs alleviates hepatocyte steatosis, inflammation, and fibrosis, indicating their critical role in NASH pathogenesis (Bartneck et al., 2015; Cynthia and Frank, 2016). Macrophages exhibit dual regulatory functions in NAFLD (Jd and Bl, 2021), offering novel insights for targeted therapies, though challenges persist (Ginhoux et al., 2022). First, macrophage phenotype classification lacks standardization. Second, specific subtypes demonstrate functional complexity and pleiotropy. For instance, while M1 macrophages promote inflammation, they also exert anti-fibrotic effects by phagocytizing debris and secreting MMP-9 to degrade ECM (Heymann et al., 2009). Therefore, clarifying macrophage subtypes and their functions is crucial for developing precise therapeutic strategies.

2.2 Neutrophils

Neutrophils are among the earliest responding immune cells in hepatic inflammation (Rawat and Shrivastava, 2022). In NASH, significant neutrophil infiltration around hepatocytes not only characterizes the disease but also correlates closely with disease progression (Nati et al., 2016). The neutrophil-to-lymphocyte ratio (NLR), as a non-invasive indicator, shows positive correlation with both the NAFLD Activity Score (NAS) and fibrosis staging (Peng et al., 2018). Neutrophils drive hepatic inflammation and directly promote fibrosis through the release of Reactive Oxygen Species (ROS), proteases, Neutrophil Extracellular Traps (NETs), and inflammatory factors (Shrestha and Hong, 2023), among which NETs play a particularly prominent role (Fa et al., 2023). Neutrophils release NETs via a death mechanism known as NETosis (Brinkmann et al., 2004). NETs not only directly cause cellular damage but also induce autoantibody production through immune complex formation, triggering secondary tissue injury (Branzk et al., 2014). Studies have demonstrated that inhibiting NET formation alleviates hepatic inflammation and fibrosis in NASH mouse models while delaying their progression to liver cancer (Zhao et al., 2020). Mechanistically, NETs activate HSCs by triggering the cyclooxygenase-2/prostaglandin E2 pathway through TLR3 signaling, thereby promoting fibrogenesis (Xia et al., 2025). Neutrophil depletion also effectively ameliorates hepatic inflammation and injury in NASH mouse models (Zang et al., 2015). Furthermore, neutrophils indirectly drive NET formation via Notch signaling, exacerbating hepatocyte senescence and lipotoxicity (Xu et al., 2025). NETs can induce intrahepatic microthrombus formation, accelerating the progression from NASH to hepatic fibrosis (Tripodi et al., 2011; Du et al., 2022). This process is associated with their promotion of thrombin and fibrin generation, upregulation of tissue factor expression, and activation of coagulation factor XII (Folco et al., 2018; Shi et al., 2021). Currently, whether NETs-mediated coagulation abnormalities can serve as therapeutic targets for alleviating NASH fibrosis remains understudied and warrants further investigation.

2.3 Dendritic cells

DCs are specialized antigen-presenting cells that sense immune microenvironment changes, recognize pathogens, and detect inflammatory signals (Jenne and Kubes, 2013; Arrese et al., 2016). By transporting phagocytosed antigens to lymphoid organs and activating naive T cells, they bridge innate and adaptive immune responses (Wang H. et al., 2021). In the liver, DCs not only participate in inducing immune tolerance and regulating T cell responses (Bernsmeier and Albano, 2017; Tong et al., 2023), but also modulate intrahepatic homeostasis and the fibrotic process (Connolly et al., 2009).

In healthy livers, DCs are relatively sparse and exhibit limited capabilities in antigen phagocytosis and T cell stimulation. They primarily maintain tolerance to self-antigens by secreting IL-10 and IL-27 to promote regulatory T cell differentiation (Bernsmeier and Albano, 2017; Méndez-Sánchez et al., 2020). During NASH development, the number of hepatic DCs increases significantly, accompanied by an expansion of classical DC (cDC) progenitor cells in the bone marrow and bloodstream (Deczkowska et al., 2021). Notably, patients exhibit a substantial accumulation of XCR1-expressing cDC1s, whose abundance positively correlates with NASH severity (Deczkowska et al., 2021). Depletion of cDC1s alleviates hepatic inflammation in murine NASH models (Deczkowska et al., 2021). Activated DCs exhibit pro-inflammatory characteristics, releasing inflammatory factors and activating antigen-specific T cells, thereby exacerbating hepatic inflammation (Henning et al., 2013; Deczkowska et al., 2021). Furthermore, lipid accumulation within DCs triggers autoimmune responses, shifting DCs from a tolerogenic state to an immunogenic phenotype (Nati et al., 2016). Accumulated lipids provide precursors for eicosanoid synthesis (e.g., prostaglandins and leukotrienes) (Saka and Valdivia, 2012), while enhancing antigen-presenting function (Anderson and Roche, 2015).

Conversely, some studies report that DCs may also ameliorate NASH-related hepatic inflammation and fibrosis (Henning et al., 2013). For instance, depletion of DCs instead accelerated the progression of hepatic fibrosis (Lukacs-Kornek and Schuppan, 2013), with research indicating that DCs can reverse chemically-induced liver fibrosis through MMP-9 secretion. Specific clearance of DCs delayed fibrosis resolution (Jiao et al., 2012). Therefore, the role of DCs in NASH pathogenesis remains controversial, as DC depletion exhibits opposing effects across different studies. The precise mechanisms by which DCs intervene in NASH require further in-depth investigation.

2.4 T lymphocytes

T lymphocytes originate from hematopoietic multipotent stem cells in the bone marrow and can be classified into two subsets: CD4⁺ T lymphocytes and CD8⁺ T lymphocytes. Upon binding to MHC-II, CD4⁺ T lymphocytes differentiate into multiple subsets including helper T cell 1 (Th1), Th2, Th17, and regulatory T cells (Tregs); while CD8⁺ T lymphocytes are also termed cytotoxic T cells (CTLs) (Nati et al., 2016). Dysregulation of CD4⁺ T lymphocytes represents one characteristic feature in the progression of chronic liver diseases (Ficht and Iannacone, 2020). Th17 and Tregs constitute crucial CD4⁺ T lymphocyte subsets involved in NASH pathogenesis regulation. Under physiological conditions, Th17 and Tregs maintain a balanced state (Świderska et al., 2017). Th17/Treg imbalance leads to deterioration of NAFLD/NASH (Josefowicz et al., 2012; Chackelevicius et al., 2016). Inflammatory CXCR3⁺ Th17 cells accumulate in the liver, driving NAFLD progression to NASH through cytokine release and macrophage activation (Moreno-Fernandez et al., 2021). Studies indicate that the intrahepatic and peripheral Th17/Treg ratio in NAFLD patients reflects disease severity and progression risk (He et al., 2017). However, the role of Treg in NASH remains controversial, with traditional views emphasizing its anti-inflammatory function (Wachtendorf et al., 2024), yet research (Dywicki et al., 2022) conversely demonstrates that Treg supplementation exacerbates hepatic inflammation in murine NASH models and activates HSCs via the amphiregulin (Areg)-epidermal growth factor receptor (EGFR) pathway (Savage et al., 2024).

CD8⁺ T cells predominantly exert pro-inflammatory effects in NASH by secreting cytotoxic molecules such as IFN-γ, TNF-α, and perforin to induce target cell apoptosis (Wong and Pamer, 2003). NASH patients exhibit increased numbers of activated CD8⁺ T cells in both hepatic tissues and systemic circulation (Bhattacharjee et al., 2017). Notably, CXCR6⁺ CD8⁺ T cells exacerbate hepatic inflammation through an acetate-driven gut-liver axis (Dudek et al., 2021). Depletion of CD8⁺ T cells reduces the risk of NASH-associated HCC development (Pfister et al., 2021). However, some studies indicate that specific CD8⁺ tissue-resident memory T cells (CD8⁺ Trm) can alleviate fibrosis by inducing apoptosis in activated HSCs (Koda et al., 2021). Furthermore, CD8⁺ T cell function is regulated by the metabolic environment: it activates HSCs in high-fat diet (HFD) models but does not significantly alter liver injury or fibrosis levels in choline-deficient high-fat diet (CD-HFD) models (Breuer et al., 2020). Evidently, T cells and their subsets play diverse and sometimes opposite roles in NASH, which involves a complex immunoregulatory network. Developing strategies targeting specific T cell subsets to inhibit NAFLD may offer novel therapeutic approaches for NASH.

2.5 Natural killer T lymphocytes

Natural killer T (NKT) cells are a specialized T cell subpopulation that co-express T cell receptors (TCR) and NK cell receptors (Zhang and Zhang, 2020), capable of recognizing lipid antigens (such as endogenous sphingolipids or exogenous α-galactosylceramide) presented by CD1d molecules through semi-invariant TCRs (Hung et al., 2017). NKT cells can be categorized into two main subtypes: invariant (iNKT) and diverse (dNKT), with the former typically dominating pro-inflammatory responses while the latter exhibits anti-inflammatory regulatory functions (Tang et al., 2022).

During NAFLD progression, NKT cells demonstrate distinct stage-specific and context-dependent characteristics. During the simple fatty liver stage, iNKT cells suppress macrophage M1 polarization by producing anti-inflammatory factors such as IL-4 and IL-10. When the disease progresses to NASH, the lipotoxic microenvironment (e.g., free fatty acids and oxidized lipids) induces upregulation of CD1d expression in hepatocytes, thereby activating NKT cells (Tajiri and Shimizu, 2012). Activated NKT cells explosively secrete pro-inflammatory factors including IFN-γ, TNF-α, and IL-17, while recruiting neutrophils and monocytes via chemokine pathways, thereby exacerbating hepatic inflammation. (Arrenberg et al., 2011; Maricic et al., 2015; Mathews et al., 2016). Moreover, iNKT cells can directly activate HSCs through the Hedgehog signaling pathway (Nimmerjahn et al., 2005), and promote fibrogenesis via mediators such as osteopontin (OPN) (Marrero et al., 2015). Notably, IL-4 derived from NKT cells induces GARP protein expression on HSCs, thereby activating TGF-β signaling and driving hepatic fibrosis. Traj18 gene knockout in mice leads to NKT cell deficiency, consequently suppressing GARP expression on HSCs and ultimately delaying NASH progression (Zhang et al., 2023).

NKT cell functionality is also modulated by GM: Bacteroides-derived lipid antigens regulate their activation state (Wieland Brown et al., 2013; An et al., 2014). Fecal microbiota transplantation experiments demonstrate that GM from alcoholic hepatitis patients can induce liver injury in mice, while restructuring the GM prevents alcohol-induced liver injury (Llopis et al., 2016). However, the specific mechanisms underlying microbiota–NKT cell interactions remain to be elucidated (Marrero et al., 2018). Notably, NKT cells constitute 20%–30% of lymphocytes in mouse livers, but account for less than 5% in human livers (Exley and Koziel, 2004). Therefore, extrapolating pathological significance from mouse models to humans requires particular caution. Future research should prioritize validation with human-derived samples and conduct in-depth analyses of regulatory mechanisms among different NKT cell subsets within disease microenvironments.

3 Crosstalk between gut microbiota and immunity in NAFLD

GM participates in the onset and progression of NAFLD through the Gut-Liver Axis (Wu et al., 2021). GM dysbiosis and intestinal barrier damage facilitate the entry of microbial metabolites into systemic circulation, including LPS, peptidoglycan, bacterial DNA, EVs, and trimethylamine N-oxide (TMAO), which activate hepatic immunity and promote inflammation (Song and Zhang, 2022). Certain metabolites, including SCFAs, bile acids (BAs), and tryptophan metabolites, exhibit anti-inflammatory and hepatoprotective effects (Stiglund et al., 2019). Intervention targeting GM has become a crucial strategy for NAFLD treatment (Agus et al., 2021), and their interaction mechanisms with immunity offer new directions for future therapies. As shown in Figure 3.

FIGURE 3

3.1 Alterations in gut microbiota composition and abundance in non-alcoholic fatty liver disease

GM exhibits significant inter-individual variations, which are closely associated with geographical regions, dietary patterns, and other factors (Sarfraz et al., 2022; Procházková et al., 2024). For example, a study of populations across different regions in China revealed (Zhang J. et al., 2024) that northern residents exhibited higher abundance of Bifidobacterium in their GM, while southern residents showed enrichment of Blautia and Lachnospiracea incertae sedis, potentially associated with differences in dietary habits. GM directly influences the efficacy of botanical drugs, and its biotransformation capabilities are crucial for the metabolites derived from botanical drugs to exert therapeutic effects. Variations in GM composition and metabolic functions among individuals may lead to inconsistent therapeutic outcomes from identical botanical drug interventions. For instance, ginsenoside Rb1 requires transformation by specific bacterial strains into the highly active Compound K to exert anticancer effects, the absence of these specific bacteria compromises the efficacy of ginsenoside intake (Wan et al., 2017). Significant differences exist in GM composition between NAFLD patients and healthy individuals (Quesada-Vázquez et al., 2022). The pathogenesis of NAFLD is negatively correlated with the alpha-diversity of GM (Alferink et al., 2021). Multiple studies indicate that NAFLD development is associated with reduced GM diversity and alterations in specific bacterial genera: Ruminococcaceae and Veillonellaceae show positive correlation with hepatic fibrosis severity and demonstrate pro-NAFLD effects in mouse models (Lee et al., 2020).

GM structure undergoes dynamic changes across different pathological stages of NAFLD. During NAFLD progression, Gram-negative bacteria (particularly LPS-producing genera such as Escherichia, Prevotella) increase, while SCFA-producing Gram-positive bacteria (e.g., Ruminococcaceae) decrease (Li F. et al., 2021). Notably, through comparative analysis of GM between NAFLD patients and non-NAFLD individuals, researchers proposed Phascolarctobacterium, Slackia, and D. formicigenerans as biological signatures of NAFLD patients (Leung et al., 2022). However, the small sample size necessitates further validation of these conclusions. During the NASH stage, the abundance of Clostridium coccoides significantly increases, and hepatic fibrosis progression exhibits a positive correlation with Ruminococcus abundance (Boursier et al., 2016). Patients with hepatic fibrosis show reduced abundance of Enterococcus faecalis and Faecalibacterium prausnitzii. Butyrate produced by these bacteria plays a crucial role in maintaining intestinal barrier integrity (Kwan et al., 2022). Studies indicate that compositional characteristics of GM can differentiate between early and late stages of hepatic fibrosis (Loomba et al., 2017). Stable GM helps maintain hepatic immune tolerance and suppresses excessive inflammation, whereas GM dysbiosis can induce chronic hepatitis and promote the formation of a microenvironment conducive to NAFLD progression. Targeting GM to modulate the immune system has become a novel strategy for NAFLD treatment. For instance, Bifidobacterium exerts immunomodulatory effects by upregulating regulatory T cells, enhancing intestinal barrier function, and suppressing the activity of macrophages and dendritic cells (Gavzy et al., 2023). GM also provides new therapeutic targets for NAFLD-associated HCC. Modulating GM can influence immune regulatory molecules on T cell surfaces, thereby enhancing the efficacy of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 and anti-CTLA-4 therapies) in HCC treatment (Huang M. et al., 2025). Although the mechanisms linking GM with NAFLD remain incompletely elucidated, GM-targeted intervention strategies undoubtedly hold broad application prospects.

3.2 GM-derived metabolites

3.2.1 LPS

LPS plays a critical role in the onset and progression of NAFLD (Carpino et al., 2020; Ji et al., 2020). Following intestinal barrier damage, LPS translocates into the portal circulation. By binding to Toll-like receptor 4 (TLR4) on HSCs and KCs, it activates the NF-κB signaling pathway, promoting the expression of inflammatory factors and fibrogenic factors, thereby exacerbating hepatic inflammation and fibrosis (Reid et al., 2016). Beyond TLR4, LPS can also bind to lipopolysaccharide-binding protein (LBP), facilitating the formation of the CD14-TLR4 complex and further enhancing inflammatory responses (Csak et al., 2011). Studies demonstrate that blocking the LPS-TLR4 signaling pathway or reducing plasma LPS levels with polymyxin B significantly alleviates liver injury and steatosis in mice (Pappo et al., 1992; Xu et al., 2023). LPS also accelerates hepatic fibrosis progression by upregulating TGF-β expression, activating the small mother against decapentaplegic (Smad) pathway, and promoting transcription of type I and III collagen (Zhong et al., 2022). For instance, Escherichia coli-derived LPS activates macrophages via the TLR4 pathway, exacerbating liver injury, whereas inhibition of this pathway markedly mitigates hepatic lesions (Carpino et al., 2020). On the other hand, LPS also participates in immunomodulatory processes and can induce endotoxin tolerance. Through the LPS/TLR4 pathway, it promotes the expansion of monocyte-derived myeloid-derived suppressor cells (mMDSCs) in the liver and downregulates T cell populations, thereby modulating local immune responses (Schneider et al., 2022). LPS promotes CD14⁺ CD8⁺ T cells to secrete protective cytokines such as IL-6 and IL-33, and influences immune cell chemotaxis (Pallett et al., 2023). These effects are closely associated with decreased TLR4 and IRAK expression, along with altered p65/p50 ratios in NF-κB (Fan and Cook, 2004).

3.2.2 Peptidoglycan

Peptidoglycan (PG), derived from gut bacteria in the host intestinal tract, constitutes the core structural component of bacterial cell walls (Meroueh et al., 2006). The diversity of GM gives rise to various types of PG (Krueger et al., 1982). As microbe-associated molecular patterns (MAMPs), PG can activate pattern recognition receptors TLR2, NOD1, and NOD2, thereby eliciting immune responses (Wagner and Cresswell, 2012; Juárez-Verdayes et al., 2013). NOD1 recognizes iE-DAP fragments while NOD2 identifies MDP fragments; both receptors activate NF-κB/MAPK signaling pathways, promote hepatic inflammation, and contribute to NAFLD progression (Travassos et al., 2004; Al Nabhani et al., 2017; Keestra-Gounder and Tsolis, 2017). In immune regulation, NOD1 perceives nutritional signals and drives neutrophil migration toward the liver, exacerbating inflammatory reactions (Dharancy et al., 2010; Meli et al., 2014). Notably, during advanced NAFLD stages, NOD1 promotes OX40L expression through metabolic reprogramming, upregulates CD8⁺ T cell activity, and thereby enhances immune responses to combat HCC (Zhang F. et al., 2024). In contrast, NOD2 primarily maintains GM balance and epithelial barrier homeostasis (Balasubramanian and Gao, 2017). Its activation stimulates Paneth cells to produce antimicrobial peptides (e.g., α-defensins) and enhances mucus secretion by goblet cells, thereby restricting bacterial translocation (Tan et al., 2015). Furthermore, NOD2 participates in host defense by modulating the MDP–NF-κB axis while moderately suppressing excessive TLR2 activation, thus alleviating intestinal inflammation (De Bruyn and Vermeire, 2017), this mechanism has been explored for therapeutic application in Crohn’s disease (Al Nabhani et al., 2020). Metabolically, NOD1 activation promotes metabolic inflammation and insulin resistance, whereas NOD2 exhibits anti-inflammatory and metabolic protective effects. This process requires the involvement of Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) (Cavallari et al., 2020). Therefore, targeting the PG–NOD1/NOD2 signaling pathways may offer novel therapeutic strategies for NAFLD.

3.2.3 Bacterial DNA

As PAMPs, bacterial DNA enters host endosomes through various endocytic pathways. Within endosomes, TLR9 recognizes bacterial DNA-derived CpG oligonucleotides, initiating the MAPK/NF-κB pathway and triggering inflammatory factor secretion (Gomes et al., 2016; Mridha et al., 2017). Moreover, TLR9 signaling can interfere with IRF7 phosphorylation through the IKKα–LC3 pathway, thereby inducing the production of Type I interferon (Hayashi et al., 2018). Additionally, the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway can also recognize bacterial DNA (Zhang and Zhang, 2025). Bacterial DNA triggers dsDNA formation, which then activates cGAS by forming a complex. This activation generates the second messenger cGAMP, which binds to STING to activate TBK1. TBK1 phosphorylates both STING and the IRF3 transcription factor. Phosphorylated IRF3 induces Type I interferon synthesis, while STING accelerates NF-κB activation through IκBα phosphorylation (Zhang and Zhang, 2025). This collectively indicates that bacterial DNA can activate innate immune responses through multiple signaling pathways, playing a significant driving role in the onset and progression of NAFLD.

3.2.4 Extracellular vesicles

GM-derived EVs are bilayer membrane-structured nanoparticles released by bacteria, carrying substantial amounts of toxic microbial molecules. These particles can traverse the compromised intestinal barrier into circulation, target the liver, and participate in NAFLD pathogenesis by activating immune-inflammatory responses (Yáñez-Mó et al., 2015). Components such as LPS carried by EVs can enter the cytoplasm via the TLR4–TRIF–GBP3 pathway, activate Caspase-11, and induce inflammation through receptors including TLR2 and NOD1/2 (Bielig et al., 2011; Gu et al., 2019). Furthermore, EVs can promote hepatic inflammation and fibrosis through the TLR4 and NLRP3–GSDMD signaling pathways (Dorner et al., 2024). EVs derived from feces of NASH patients (NASH-fEVs) disrupt intestinal barrier integrity, increase permeability, and activate HSCs via the TLR/LPS pathway, thereby upregulating fibrosis-related protein expression (Fizanne et al., 2023). Notably, the impact of EVs on the liver is context-dependent: for instance, miRNA (miR-129-2-3p) derived from Fusobacterium nucleatum can exacerbate intestinal inflammation by promoting cellular senescence (Wei et al., 2023). Conversely, remodeling GM using the PPARα inhibitor GW6471—which increases the abundance of probiotics (e.g., Bacteroides) while reducing harmful bacterial populations—alleviates hepatic lipid accumulation, ferroptosis, and oxidative stress, thereby improving NAFLD (Yang X. et al., 2025). In summary, EVs exhibit dual roles in NAFLD, where their specific effects are contingent upon both their microbial origin and the host microenvironment. Further investigation into the immune-regulatory mechanisms of active components within EVs will help elucidate their pathological significance and therapeutic potential in NAFLD.

3.2.5 Indole and its derivatives

Intestinal tract commensal bacteria metabolize tryptophan (Trp) into various indole derivatives, including indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), indole-3-aldehyde (IAld), indole-3-lactic acid (ILA), and tryptamine (Su et al., 2022). Different bacteria possess distinct tryptophan enzymes that produce specific indole derivatives (Dodd et al., 2017). Indole derivatives accumulate in the intestinal tract and activate the Aryl Hydrocarbon Receptor (AhR) on innate lymphoid cells, thereby promoting goblet cell differentiation and mucus secretion (Powell et al., 2020), and induce tight junction protein expression (Shimada et al., 2013), enhancing the integrity and functionality of the intestinal barrier. On the other hand, AhR is widely expressed in various immune cells, such as DCs, T cells, and lymphocytes (Nguyen et al., 2010; Rothhammer and Quintana, 2019), mediating the regulation of the immune system by indole derivatives, including promoting Treg differentiation (Goettel et al., 2016), inducing T cell apoptosis (Landfried et al., 2011), and suppressing the inflammatory activity of Th17 cells (Rothhammer and Quintana, 2019), thereby alleviating hepatic inflammation. Furthermore, indole derivatives (e.g., IAA and IPA) produced by specific strains (e.g., probiotics) inhibit the NF-κB pathway, reduce levels of pro-inflammatory factors (IL-8), and promote the release of anti-inflammatory factors (IL-10) (Bansal et al., 2010). Clinical studies have revealed decreased levels of IPA and IAA in the feces of NAFLD patients. Increasing the abundance of Bifidobacterium bifidum—the primary source of these metabolites—significantly ameliorates hepatic steatosis and inflammation in mice (Min et al., 2024). Furthermore, indole derivatives promote the proliferation of intestinal crypt epithelial-tubular cells in mice, which plays a critical role in maintaining intestinal immune homeostasis (Powell et al., 2020).

3.2.6 Bile acids

BAs are important signaling molecules generated through enzymatic conversion of cholesterol in the liver. By activating specific receptors, they regulate hepatic lipid metabolism and suppress the transcription of inflammatory factors, thereby influencing NAFLD progression. Among these, Farnesoid X Receptor (FXR) and Takeda G-protein Receptor 5 (TGR5) represent two critical BAs receptors (Chávez-Talavera et al., 2017). FXR plays a pivotal role in anti-inflammatory and immunomodulatory processes, BAs activate FXR to suppress NF-κB signaling, thereby reducing its induction of inflammatory mediators such as IFNγ and COX-2 (Wang et al., 2008). This downregulates monocyte chemoattractant protein-1 (MCP-1) expression, diminishing macrophage infiltration into the liver (Li et al., 2015). Simultaneously, FXR activation restores the intestinal vascular barrier by triggering the endothelial Wnt/β-catenin pathway, which blocks bacterial translocation and alleviates hepatic inflammation (Mouries et al., 2019). FXR signaling also acts on macrophages, NK cells, and DCs, restricting the production of pro-inflammatory factors and suppressing inflammasome activation (Sun et al., 2021; Fiorucci et al., 2022). Since TGR5 is widely distributed in cell types including HSCs, LSECs, and macrophages (Keitel et al., 2007). TGR5 activated by BAs promotes macrophage M2 polarization (Shao et al., 2022), inhibits the TLR4–NF-κB pathway (Biagioli et al., 2017; Hosseinkhani et al., 2021), suppresses NLRP3 inflammasome activation and IL-1β secretion through the cAMP–PKA signaling axis (Pols et al., 2011; Guo C. et al., 2016), and induces endothelial nitric oxide synthase (eNOS) expression to exert anti-inflammatory effects (Keitel et al., 2007). Additionally, TGR5 promotes the release of glucagon-like peptide-1 (GLP-1) in the intestinal tract, thereby improving insulin sensitivity and lipid metabolism (Thomas et al., 2009). Notably, BAs with different structures exhibit distinct effects, for example, 12α-hydroxylated BAs (12α-OH BAs) paradoxically promote HSCs proliferation by binding to TGR5. Simultaneously, they upregulate hepatic fibrosis-related proteins (α-SMA, TGF-ß, COL I, PDGF) and exacerbate fibrosis progression through activation of ERK1/2 and p38 MAPK signaling pathways (Xie et al., 2021).

3.2.7 Short-Chain fatty acids

SCFAs modulate immune and metabolic responses through multiple pathways, thereby influencing the progression of NAFLD. SCFAs promote proliferation of intestinal epithelial cells, enhance expression of tight junction proteins (e.g., ZO-1, occludin, claudin-1, and claudin-2), and activate hypoxia-inducible factor (HIF) to maintain intestinal barrier integrity (Nicolas and Chang, 2019). Butyrate also induces expression of the antimicrobial peptide β-defensin-1, reducing levels of LPS-carrying bacteria and LPS (Beisner et al., 2021). Furthermore, it inhibits the increase in intestinal permeability mediated through the TLR4/myeloid differentiation factor (MyD88) signaling pathway (Nighot et al., 2017). SCFAs deficiency impairs barrier function by causing inadequate energy supply to intestinal epithelium and disrupting mucosal immune homeostasis (Matsumoto et al., 2017).

Secondly, SCFAs regulate immune cell function through G protein-coupled receptors (GPRs) and Toll-like receptors (TLRs) (Canfora et al., 2015). For instance, butyrate promotes anti-inflammatory factor IL-10 secretion and Treg differentiation via GPR109a, while suppressing release of inflammatory factors such as IL-1β, IL-6, and TNF-α through TLR4 (Feingold et al., 2014; Sam et al., 2021). SCFAs also promote Treg differentiation via epigenetic mechanisms including HDAC inhibition and enhanced histone H3 acetylation in the Foxp3 promoter region, thereby ameliorating hepatic inflammation (Furusawa et al., 2013; Park et al., 2015). Supplementation of butyrate-producing Clostridium butyricum B1 (CB) in the NASH mouse model reversed HFD-induced hepatic steatosis, suppressed hepatic MCP-1 and TNF-α expression, reduced pro-inflammatory factors (IFN-γ and IL-17) in both liver and intestinal tract, and increased anti-inflammatory factors (FOXP3⁺, IL-4, and IL-22). These findings were corroborated by in vitro experiments (Zhou et al., 2017).

Additionally, SCFAs intervene in NAFLD through energy metabolism regulation. SCFA supplementation ameliorated hepatic steatosis in mice (Shimizu et al., 2019). Acetate and propionate stimulate peptide YY (PYY) and insulin-like growth factor-1 (IGF-1) release via GPR41/43, thereby suppressing appetite and energy intake. Concurrently activates AMP-activated protein kinase (AMPK) to reduce lipid accumulation (Deng et al., 2020). Sodium butyrate regulates hepatic lipid metabolism by promoting GLP-1 secretion from intestinal L cells (Zhou et al., 2018). Clostridium butyricum capsules combined with rosuvastatin demonstrate superior efficacy over monotherapy in lipid regulation, anti-fibrotic effects, and liver function improvement (Zhu et al., 2022). Notably, acetate promotes liver regeneration by inducing SCD1 expression (Yin et al., 2023), providing novel directions for NAFLD treatment.

3.2.8 TMAO

Circulating TMAO levels exhibit positive correlations with NAFLD incidence risk, disease severity, and all-cause mortality (Flores-Guerrero et al., 2021). TMAO promotes NAFLD progression through multiple mechanisms. TMAO elevates mitochondrial ROS levels, activates the NF-κB signaling pathway, thereby promoting NLRP3 inflammasome assembly and the release of inflammatory factors such as IL-1β. It also disrupts calcium homeostasis in pancreatic β-cells, leading to dysfunction (Kong et al., 2024). Secondly, TMAO impairs intestinal barrier function by suppressing the Wnt/β-catenin pathway and activating TLR4/MyD88/NF-κB signaling. Simultaneously, it induces LSEC dysfunction and capillarization, while promoting macrophage M1 polarization (Nian et al., 2024). Research reveals that TMAO activates the PERK signaling pathway in zebrafish liver and HepG2 cells, inducing pathological alterations including lipid accumulation, inflammation, and fibrosis (Yang et al., 2024). TMAO triggers endoplasmic reticulum stress (ERS), activates macrophages via the TLR pathway, and exacerbates inflammatory responses (Hakhamaneshi et al., 2021). Concurrently, TMAO suppresses BAs synthesis, disrupts cholesterol metabolism, aggravates intrahepatic lipid accumulation, promotes foam cell formation, and inhibits reverse cholesterol transport (RCT), thereby further compromising hepatic lipid homeostasis (Janeiro et al., 2018). Reduced TMAO synthesis can lower the risk of NAFLD onset and progression (Corbin and Zeisel, 2012).

4 Botanical drugs and their metabolites alleviate the progression of non-alcoholic fatty liver disease by modulating the gut microbiota-immune responses axis

Currently, botanical drugs and their metabolites are receiving increasing attention as adjuvant therapies. Through synergistic effects, they regulate multiple interconnected targets and pathways within the disease network, promoting the restoration of immune system balance and thereby reducing hepatic inflammation (Zhi et al., 2025). Numerous studies indicate they can intervene in NAFLD progression via the GM-immune responses axis.As shown in Tables 1, 2.

4.1 Metabolites originating from botanical drugs

4.1.1 Berberine

Berberine (BBR), a natural metabolite derived from Coptis chinensis Franch., alleviates hepatic inflammation by targeting GM. Administration of BBR (40 mg/kg) to NAFLD mouse models increased the relative abundance of Akkermansia and Bacteroides at the genus level, while decreasing the relative abundance of Lactobacillus and Romboutsia (Yang et al., 2022). BBR supplementation elevated intestinal Bifidobacterium abundance and Bacteroidetes/Firmicutes ratio in NASH mouse models, concurrently reducing serum concentrations of inflammatory factors including IL-1, IL-6, TNF-α, and CD14 (Cao et al., 2016). The study also found that BBR supplementation reduced the abundance of F. prausnitzii (Li et al., 2017). Regarding intestinal barrier function, BBR promotes the expression of tight junction proteins (ZO-1 and Occludin), increases the number of colonic glands and mucus secretion by goblet cells, reduces translocation of Gut-Derived LPS to the liver, and alleviates hepatic inflammation (Chen D. et al., 2023; Chen et al., 2023 Y.). Beyond regulating GM, BBR exerts effects through direct anti-inflammatory and anti-fibrotic mechanisms, including inhibition of JNK1 signal transduction (Guo T. et al., 2016) and downregulation of TLR4/MyD88/NF-κB pathway activity (Wang L. et al., 2020), reducing the expression and activity of neutrophil elastase (NE), upregulating α1-antitrypsin (α1-AT), and inhibiting the CXCR4/CXCL12 axis (Yang et al., 2017), as well as inducing apoptosis of HSCs and suppressing their proliferation (Eissa et al., 2018). Animal studies demonstrate that BBR supplementation (200 mg/kg/d) significantly alleviates hepatic inflammation and steatosis in HFD-induced NASH mouse models, with these effects closely linked to GM modulation and intestinal barrier repair. (Cao et al., 2016). A clinical trial involving 184 NAFLD patients further confirmed that oral BBR administration (1.5 g/d for 16 weeks) significantly reduced hepatic fat content, lipid parameters (TG, TC), and liver enzyme levels (ALT, AST), while exhibiting a favorable safety profile (Yan et al., 2015). BBR demonstrates promising therapeutic potential for NAFLD/NASH prevention and treatment through multi-target modulation of GM, enhancement of barrier function, and suppression of inflammatory signaling pathways and fibrotic progression.

4.1.2 Resveratrol

Resveratrol (RSV), a natural polyphenolic metabolite primarily extracted from Reynoutria japonica Houtt., exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties (Tian and Liu, 2020). As a natural agonist of silent information regulator 1 (SIRT1), RSV ameliorates hepatic lesions by exerting anti-inflammatory and anti-fibrotic effects through multiple pathways. In hepatocytes, RSV significantly alleviates hepatic inflammation by activating the AMPKα–SIRT1 signaling pathway to inhibit the NF-κB inflammatory pathway (Tian et al., 2016). Simultaneously, RSV induces apoptosis of activated HSCs and suppresses their activation in a dose-dependent manner via the SIRT1 and JNK signaling pathways, thereby reversing hepatic fibrosis (Zhang et al., 2022). On the other hand, RSV also exerts significant regulatory effects on immune cells. It interferes with interferon-gamma (IFN-γ)-mediated macrophage activation by inhibiting the JAK/STAT-1 pathway, consequently reducing the production of inflammatory mediators such as nitric oxide (NO), IP-10, and MIG, while downregulating the expression of inducible nitric oxide synthase (Chung et al., 2011). Additionally, RSV promotes macrophage polarization toward the M2 anti-inflammatory phenotype and upregulates IL-10 synthesis, thereby alleviating fibrosis (Yu et al., 2019; Jin et al., 2025). Furthermore, RSV inhibits NF-κB nuclear translocation and reduces inflammatory factor release by disrupting crosstalk between the TLR2/MyD88/ERK and NF-κB/NLRP3 inflammasome pathways, thereby delaying the progression of hepatic fibrosis (Lei et al., 2025). Regarding intestinal effects, RSV not only remodels GM and enhances microbial diversity but also strengthens intestinal mucosal barrier function by upregulating tight junction proteins (Occludin, ZO-1, and Claudin1). It concurrently suppresses mRNA expression of cannabinoid receptor type 1 (CB1), further consolidating its protective effects along the gut-liver axis (Chen et al., 2020).

Supplementation with RSV (50/75/100 mg/kg/d) significantly reduced hepatic steatosis and fibrosis in HFD-induced NASH rats, with the ameliorative effect demonstrating dose dependency. RSV restructured the GM composition in NASH rats. At the species level, the abundance of Akkermansia muciniphila increased; at the genus level, Bacteroides abundance increased while Desulfovibrio abundance decreased; at the family level, Ruminococcaceae and Lachnospiraceae abundances increased. However, these GM alterations were not observed in the low-dose RSV group (50 mg/kg/d) (Campbell et al., 2019). The study also found that RSV supplementation reduced the abundance of harmful bacteria Desulfovibrio, Lachnospiraceae_NK4A316_group, and Alistipes in the intestinal tract, while increasing the abundance of SCFA-producing bacteria Allobaculum, Bacteroides, and Blautia (Wang P. et al., 2020). An RCT involving 60 NAFLD patients demonstrated that 3 months of RSV supplementation (300 mg/d) significantly reduced serum levels of ALT, AST, TC, and TNF-α (Chen et al., 2015).

4.1.3 Curcumin

Curcumin (Cur), a natural metabolite extracted from Curcuma longa L., exhibits multiple biological activities including antioxidant, anti-inflammatory, and antitumor effects. Cur intervenes in NAFLD progression through multiple mechanisms, including anti-inflammatory effects, regulation of lipid metabolism, improvement of insulin resistance, and modulation of fibrotic processes (Li X. et al., 2024). In recent years, its role in modulating GM has garnered increasing attention. Studies demonstrate that Cur significantly increases Bacteroides abundance and ameliorates hepatic lipid accumulation through microbiota-dependent BAs metabolism (He et al., 2024). In NAFLD models, Cur reverses the elevated Firmicutes/Bacteroidetes ratio and reduced Akkermansia abundance (Hong et al., 2022), while concurrently upregulating expression of tight junction proteins Occludin and ZO-1, suppressing TLR4/NF-κB pathway activation, and reducing LPS exposure, thereby alleviating hepatic inflammation (Hong et al., 2022). Further studies (Li S. et al., 2021; Hong et al., 2022) confirmed that Cur effectively ameliorated hepatic steatosis and reduced serum LPS levels in HFD-fed mice. This protective mechanism correlates with modulation of GM composition, specifically manifested through: decreased Firmicutes/Bacteroidetes ratio and reduced Desulfovibrio abundance, alongside elevated abundance of Akkermansia and multiple SCFA-producing genera including Bacteroides, Parabacteroides, Alistipes, and Alloprevotella. Cur supplementation (200 mg/kg/d for 16 weeks) significantly alleviated hepatic steatosis and oxidative stress in HFD-fed mice, mediated through multiple pathways (Yang J. et al., 2025). Cur enhanced the alpha-diversity of the GM. At the family taxonomic level, a significant increase in the abundance of Coriobacteriaceae was observed. At the genus level, the abundance of Mailhella and Parabacteroides increased, while that of Alistipes decreased. At the species level, the abundance of Phocaeicola vulgatus and Bacteroides intestinalis rose, whereas Acutalibacter muris abundance declined, thereby reducing the synthesis of enterogenic toxins. Simultaneously, Cur inhibits the JNK2/FOXO1/Bcl6 signaling axis to alleviate lipid accumulation (Yang J. et al., 2025). Moreover, Cur suppresses M1 polarization of macrophages and reduces the secretion of IL-1β and TNF-α (Tong et al., 2021). By promoting PPARα mRNA m6A methylation through inhibition of FTO protein, it activates the PPARα/CPT1α pathway to enhance fatty acid β-oxidation (Fan et al., 2025b), regulates AMPK, ChREBP, and SREBP1-c expression to ameliorate lipid metabolism (Guariglia et al., 2023), downregulates CYP2E1 and C/EBPβ, reduces ROS generation, and alleviates oxidative stress (Afrin et al., 2017). A meta-analysis encompassing 1,028 NAFLD patients also demonstrated that curcumin effectively ameliorates hepatic steatosis (Ngu et al., 2022).

4.1.4 Quercetin

Quercetin (QUE), a metabolite isolated from Scutellaria baicalensis Georgi, intervenes in NAFLD through multiple pathways. QUE reverses HFD-induced GM dysbiosis, significantly lowering the Firmicutes/Bacteroidetes ratio and reducing the abundance of Gram-negative bacteria such as Helicobacter. This diminishes endotoxemia occurrence, ultimately suppressing TLR4/NF-κB signaling pathway activation and inflammasome initiation, thereby ameliorating hepatic inflammation (Porras et al., 2017). QUE supplementation also inhibits oxidative stress in hepatocytes by regulating cytochrome P450 2E1 (CYP2E1), thereby conferring hepatoprotective effects against NAFLD (Porras et al., 2017). Conversely, QUE inhibits the NF-κB p65/iNOS signaling pathway in a concentration-dependent manner and reduces serum TNF-α levels (Ying et al., 2013). It blocks phosphorylation of IκBα and NF-κB p65 while upregulating expression of superoxide dismutase (SOD) and glutathione peroxidase 1 (GPX1), thus systematically alleviating hepatic oxidative stress and excessive immune activation (Jiang et al., 2025). Furthermore, QUE can activate the antioxidant transcription factor Nrf2 and alleviate hepatic lipid accumulation, mitochondrial dysfunction, and oxidative stress through the AMPK-dependent autophagy pathway (Panchal et al., 2012; Cao et al., 2023).

The effect of QUE on ameliorating lipid metabolism is closely associated with its promotion of beneficial A. muciniphila proliferation. Indole-3-lactic acid (ILA), produced by this bacterium’s metabolism, upregulates CYP8B1 via the FTO/m6A/YTHDF2 pathway, driving cholesterol conversion into cholic acid (CA). The latter suppresses lipid accumulation through FXR receptor activation (Liu J. et al., 2025). A randomized controlled trial (n = 41) demonstrated the clinical value of QUE. NAFLD patients supplemented with 500 mg QUE daily for 12 weeks exhibited significant reductions in hepatic lipid content, body weight, and body mass index (BMI), with favorable safety profiles (Li N. et al., 2024).

4.1.5 Lycium barbarum polysaccharides

Lycium barbarum polysaccharides (LBPs) constitute a key active metabolite in Lycium chinense Mill. LBPs delay NAFLD progression by modulating GM and enhancing barrier function. In NAFLD mouse models, LBPs reduce the relative abundance of Verrucomicrobia and Enterococcaceae (Gao et al., 2021), and the latter serves as the primary source of gut-derived LPS. This helps reduce the risk of LPS translocation and hepatic inflammation (Hu et al., 2020), while simultaneously increasing the abundance of Deferribacteres and butyrate-producing bacteria (such as Butyricicoccus and Butyricimonas) (Gao et al., 2021). Butyrate enhances the expression of intestinal mucus and tight junction proteins (ZO-1, occludin), thereby improving intestinal barrier function (Peng et al., 2007). The study (Ding et al., 2019) further confirmed that LBPs promote the proliferation of Bacteroides, Bifidobacterium, and SCFA-producing bacteria such as Phascolarctobacterium, Prevotella, and Collinsella. LBPs play a crucial role in inhibiting the progression of NAFLD.

Notably, the effects of LBPs on modulating GM are not solely determined by their metabolites; the structural domains of LBPs also exert influence. This structure-function relationship is particularly evident in Bacteroidetes and Parabacteroides. RG-I and its neutral sugar side chains increase the abundance of beneficial bacterial families such as Comamonadaceae; whereas linear homogalacturonan (HG) promotes the proliferation of potentially harmful bacterial families including Pseudomonadaceae, Xanthomonadaceae, Caulobacteraceae, and Oxalobacteraceae (Wei et al., 2025).

LBPs also stimulate putrescine secretion by murine GM, which subsequently inhibits the JAK2-STAT3 pathway via TRAF6-mediated suppression, thereby reducing Th17 cell differentiation and inflammatory factor release (Wang et al., 2025). Moreover, Th17 differentiation drives the progression from NASH to HCC, rendering the inhibition of this differentiation a crucial intervention strategy for NASH (Huang Y. et al., 2025). Supplementation with LBPs (100 mg/kg, 10 weeks) significantly alleviated liver injury, dyslipidemia, and inflammation in NASH rats. This effect was achieved by activating the AMPK/PPARα/PGC-1α pathway to promote hepatic lipid consumption (Li et al., 2022). LBP inhibited caspase-9/3 activity and TNF-α levels in CCl4-induced hepatic fibrosis mice, thereby mitigating hepatic inflammation and fibrosis (Chiang and Chao, 2018). A pre-post study also demonstrated that LBP supplementation (300 mg/day, 12 weeks) improved both GM diversity and liver function in NAFLD patients (Fan et al., 2025a).

4.1.6 Poria cocos polysaccharide

Poria cocos polysaccharide (PCP) is a botanical drug-derived metabolite (Zhao et al., 2023). PCP increases the relative abundance of Faecalibaculum, reduces gut-derived LPS levels, thereby inhibiting the NF-κB/CCL3/CCR1 signaling pathway, alleviates hepatic inflammation, and delays NASH progression (Tan et al., 2022). Furthermore, PCP reduces hepatocyte apoptosis by suppressing the CYP2E1/ROS/MAPKs signaling pathway, and decreases the liver’s exposure risk in inflammatory environments through restoration of intestinal barrier function (Jiang et al., 2022). In both zebrafish and mouse NAFLD models, PCP demonstrated efficacy in counteracting hepatic steatosis (Ye et al., 2022). This beneficial effect stems from reducing translocation of gut-derived LPS to the liver and suppressing PARP-1-mediated pyroptosis in intestinal cells. Furthermore, PCP inhibited disease progression in methionine-choline-deficient (MCD)-induced NASH mice by downregulating expression of F4/80, CD68, IL-1β, CD11b, and CCL5 genes (Gao et al., 2023). Simultaneously, PCP alleviated hepatic steatosis in NAFLD mice by modulating glucose and lipid metabolism through upregulation of lipid transport proteins and suppression of lipid synthesis-associated proteins (Wang et al., 2022). PCP is even considered a prebiotic. Supplementation with PCP (50 mg/kg/d, for 8 weeks) can alleviate insulin resistance, lipid metabolism imbalance, and inflammation in the NASH mouse model. This effect stems from PCP enhancing the intestinal barrier, improving GM diversity, and increasing the relative abundance of probiotics including Lactobacillus, Allobaculum, and Phascolarctobacterium. These probiotics synthesize SCFAs, which subsequently ameliorate insulin resistance through the FGF21-PI3K/AKT signaling pathway (Liu et al., 2025b).

4.1.7 Ginsenoside

Ginsenoside (Rg) is a metabolite extracted from Panax ginseng C. A. Mey. Rg supplementation ameliorates hepatic steatosis and reduces hepatic inflammation in HFD-induced NAFLD mouse models, with its therapeutic effects on NAFLD being closely related to modulation of the GM-immune axis (Shi et al., 2024). Studies demonstrate that Rg can restructure GM composition, and this alteration proves beneficial to host health. At the phylum level, Bacteroidota abundance increases while the Firmicutes/Bacteroidetes ratio decreases; at the family level, Muribaculaceae abundance elevates; At the genus level, the relative abundances of Akkermansia, Parabacteroides, Lachnospiraceae_NK4A136_group, Oscillospira, Phascolarctobacterium, Bacteroides, and Dehalobacterium increased, while the relative abundances of Allobaculum and Olsenella decreased (Liang et al., 2021; Shi et al., 2024). Concurrently, Rg enhances intestinal barrier integrity by upregulating the expression of tight junction proteins (including ZO-1, Occludin, and Claudin-1), thereby reducing the translocation of Gut-Derived LPS. Furthermore, Rg reduces LPS levels and inhibits the TLR4/NF-κB signaling pathway, consequently decreasing the production of pro-inflammatory factors and suppressing macrophage activation and inflammatory cell infiltration in the liver, ultimately alleviating hepatic inflammation (Liang et al., 2021).

Beyond the intestinal tract, Rg delays NAFLD progression by multi-target regulation of lipid metabolism. Regarding lipid metabolism, Rg reduces lipid uptake through suppression of CD36 expression (Wu et al., 2025) while activating the hepatic LKB1/AMPK/mTOR signaling pathway (Shi et al., 2024). This dual action cooperatively downregulates key lipid synthesis genes (e.g., SREBP-1c, FAS, ACC) and upregulates the fatty acid oxidation gene CPT-1a, thereby significantly ameliorating hepatic lipid accumulation (Liang et al., 2021; Shi et al., 2024). Furthermore, activated AMPK exerts hepatoprotective effects through metabolic and anti-inflammatory mechanisms: it inhibits mTORC1 and SREBP-1c to reduce lipid synthesis, while suppressing NF-κB signaling and oxidative stress via the sirtuin 1/FOXO1 pathway (Wu et al., 2025). Notably, lipid overload can induce ferroptosis, thereby driving the progression of NAFLD (Chen et al., 2022). Rg effectively enhances antioxidant capacity by activating the Keap1/Nrf2 signaling pathway and preserving mitochondrial structural and functional integrity, consequently inhibiting ferroptosis (Liu et al., 2025c). Significantly, the anti-ferroptosis effect of Rg markedly diminished following antibiotic intervention, indicating its dependence on GM involvement. This demonstrates that Rg primarily suppresses NAFLD development through multiple pathways by modulating the “GM–immune inflammation” axis while synergistically improving lipid metabolism and antioxidant pathways.

4.1.8 Pachymic acid

Pachymic acid (Pac) is a metabolite derived from Wolfiporia cocos (F. A. Wolf) Ryvarden & Gilb. Pac supplementation alleviated hepatic inflammation in HFD-induced NAFLD mouse models (Ren et al., 2025a). Pac reshaped the GM structure in NAFLD mice, reversing HFD-induced intestinal dysbiosis. At the phylum level, the Firmicutes/Bacteroidetes ratio decreased. At the genus level, the abundance of Akkermansia increased, while Desulfovibrio and Streptococcus decreased. Furthermore, Pac reduced the expression of hepatic inflammatory factors by suppressing the LPS/TLR4/MYD88/NFκB pathway, thereby mitigating liver inflammation. Pac inhibits the expression of lipid synthesis-related proteins including FASN, SREBP1c, and SCD1, while promoting the expression of fatty acid oxidation-related proteins such as PPARα and CPT1α, thereby reducing hepatic inflammation induced by lipid accumulation. Studies demonstrate that Pac ameliorates HFD-induced NAFLD through synergistic multi-pathway effects. In animal models, Pac supplementation (20/40 mg/kg for 4 weeks) significantly alleviates hepatic steatosis, reduces serum lipid levels, and improves liver function (Ren et al., 2025b). On one hand, Pac upregulates the expression and activity of PPARα, thereby promoting hepatic fatty acid oxidation to accelerate lipid consumption. Additionally, activated PPARα upregulates GPX4 protein expression, thus inhibiting ferroptosis. On the other hand, Pac downregulates TFR1 protein expression by inhibiting the MAPKs signaling pathway, consequently reducing Fe³⁺ uptake and intracellular Fe²⁺ accumulation in hepatocytes. This suppresses the Fenton reaction and further alleviates hepatocellular ferroptosis. Through multiple mechanisms including promoting lipid metabolism, inhibiting inflammation, and suppressing ferroptosis, Pac collectively delays the progression of NAFLD.

4.2 Botanical drugs formulae

Botanical drugs formulae comprise complex systems of multiple botanical drugs, corresponding to diverse metabolites. Their core therapeutic mechanism lies in the synergistic effects of metabolites through multi-target and multi-system interventions, achieving holistic regulation of diseases.

Zexie Tang contains two botanical drugs: Alisma plantago-aquatica L. and Atractylodes macrocephala Koidz. Researchers discovered that Zexie Tang contains a metabolite composed of fructose and glucose, designated as Zexie Tang Polysaccharides (ZXTPs) (Zhang et al., 2025). ZXTPs ameliorate hepatic steatosis in NAFLD mouse models via the gut-liver axis. ZXTPs remodeled the GM, increasing the abundance of beneficial bacteria including Akkermansia, Lachnospiraceae_NK4A136, and Bacteroides, while reducing pathogenic bacteria such as Prevotella_9 and Phascolarctobacterium. This alteration promoted the secretion of tryptophan metabolites (including indole-3-acetic acid and serotonin) and SCFAs. Tryptophan metabolites play a key role in alleviating hepatic inflammation and modulating immunity by activating AhR. Concurrently, ZXTPs upregulate the expression of tight junction proteins (ZO-1 and Occludin), repairing the intestinal mucosal barrier and thereby inhibiting gut-derived LPS from entering systemic circulation. Meanwhile, tryptophan metabolites exert crucial effects in mitigating hepatic inflammation and modulating immunity through activation of the AhR. Regarding lipid metabolism, SCFAs and ZXTPs enhance hepatic AMPK phosphorylation through regulating LKB1/AMPK and PI3K/AKT/mTOR signaling pathways along with the autophagy pathway. This subsequently suppresses expression of the lipogenesis key enzyme SREBP1 while upregulating PPARα expression, ultimately leading to significant amelioration of hepatic lipid metabolism.

Yinzhihuang granule (YZHG) contains four types of botanical drugs, including Artemisia capillaris Thunb, Gardenia jasminoides J.Ellis, S. baicalensis Georgi, Lonicera japonica Thunb. The study (Tan et al., 2023) revealed that YZHG contains 42 blood-absorbed metabolites, primarily flavonoids, phenolic acids, iridoids. YZHG could reduce blood lipid levels in NAFLD mouse models and decrease concentrations of LPS, TNF-α, IL-1β, and IL-6 in liver tissues. YZHG modulated the GM structure in mice: at the phylum level, the abundance of Firmicutes and Proteobacteria decreased, while Patescibacteria and Tenericutes increased; At the genus level, the abundance of Ruminococcaceae_UCG-014, Lactobacillus, and Desulfovibrio elevated. 16S rRNA sequencing and metabolomics demonstrated that this therapeutic effect stems from YZHG metabolites influencing intestinal tract and lipid metabolism-related proteins, particularly chrysin, baicalein, wogonin, hispidulin, and negletein A.

Xie Zhuo Tiao Zhi formula (XZTZ) contains Crataegus pinnatifida Bunge, Nelumbo nucifera Gaertn., Citrus × aurantium Siebold & Zucc. ex Engl., A. macrocephala Koidz., W. cocos (F. A. Wolf) Ryvarden & Gilb, A. plantago-aquatica L. These botanical drug-derived metabolites (including naringin, neohesperidin, atractylenolide III, 23-acetyl alisol B, pachymic acid, and ursolic acid) elevate circulating and hepatic inosine levels by increasing the abundance of A. muciniphila, Bifidobacterium pseudolongum, and Ileibacterium valens in the intestinal tract of NAFLD mouse models. This subsequently inhibits hepatocyte pyroptosis, as evidenced by downregulation of NLRP3, GSDMD, Nek7, Caspase-1, and ASC protein expression, while reducing inflammatory factors such as IL-1β, IL-6, and TNF-α. Concurrently, other metabolites (such as Inosine) effectively alleviate hepatic lipid accumulation by regulating the expression of proteins involved in lipid synthesis, transport, and oxidation (Qiu et al., 2023).

Yinchen-Gancao decoction (YG) consists of two botanical drugs: A. capillaris Thunb. and Glycyrrhiza uralensis Fisch., which carry multiple metabolites, including Chlorogenic Acid (CGA), Glycyrrhizic Acid (GZA), Isochlorogenic Acid (ICGA), and glycyrrhetinic acid (GTA). YG significantly ameliorates hepatic lipid accumulation and inflammation in the NASH mouse model. This effect stems from CGA suppressing the fatty acid synthesis pathway (SREBP1c-ACC/FASN) via an FXR-dependent mechanism, downregulating the expression of the uptake protein CD36, and enhancing lipid oxidation through the PPARα-CPT1α pathway (Jing et al., 2025).

Si-Wu-Tang (SWT) treats CCL4-induced hepatic fibrosis by remodeling the composition of GM and regulating BAs metabolism (Xue et al., 2021). Twenty-two major metabolites derived from botanical drugs in SWT, particularly paeoniflorin, ferulic acid, verbascoside, and senkyunolide A, play crucial roles. They regulate BAs metabolism by activating the FXR-fibroblast growth factor 15 (FGF15) and FXR-SHP pathways, which facilitates hepatic lipid excretion and reduces lipotoxicity-induced inflammation. Conversely, paeoniflorin and ferulic acid synergistically improve the intestinal microenvironment, at the phylum level, the abundance of Bacteroides and Lachnoclostridium increases; at the genus level, the abundance of Alistipes decreases. At the family level, reduced abundance of Rikenellaceae suppresses gut-derived endotoxin translocation, thereby alleviating hepatic inflammation burden.

Lingguizhugan decoction (LGZG) can alleviate hepatic inflammation in HFD-fed mice. This effect is closely associated with metabolites derived from botanical drugs, including Paclitaxel (Pac), Cinnamaldehyde, Atractylenolide II, and Glycyrrhizic acid (GZA). These metabolites inhibit TNFα and IFNβ release in a dose-dependent manner; Notably, both Cinnamaldehyde and GZA further block activation of the STING–TBK1–NF-κB signaling pathway by suppressing TBK1 and NF-κB phosphorylation in macrophages. Notably, the effects of mixed metabolites surpassed those of single metabolites, indicating synergistic interactions among metabolites (Cao et al., 2022). Yindanxinnaotong (YDX) comprises eight botanical drugs containing a total of 124 metabolites. Studies demonstrate that YDX reduces gut-derived LPS production by remodeling the GM. At the genus level, it significantly increases the abundance of Odoribacter, Alistipes, and Flavonifractor while decreasing Clostridium cluster XIVa and Barmesiella. Furthermore, YDX downregulates hepatic expression of lipid synthesis-related proteins (including SREBP-1c, SCD-1, and CD36) and pro-inflammatory cytokines (IL-6, TNF-α), while enhancing expression of key fatty acid β-oxidation proteins (AMPKα, CPT-1). This effectively suppresses hepatic lipid accumulation and inflammatory responses (Huang et al., 2024). Although studies have observed alterations in GM alongside improvements in hepatic lipid metabolism and inflammatory status, the direct link between these two pathways, the primary metabolites involved, and the specific mechanisms remain to be elucidated, this warrants further investigation.

Shugan Xiaozhi (SG), composed of 15 botanical drugs, is commonly employed in the treatment of NAFLD. SG ameliorates hepatic inflammation and fibrosis in HFD-induced mice, suppresses intrahepatic ROS generation, elevates levels of SOD, GSH, and CAT, reduces MDA levels in murine liver in a dose-dependent manner, and preserves the integrity of hepatic mitochondrial function and structure. These effects depend on SG’s regulation of BNIP3/BNIP3L-mediated mitophagy. Metabolites derived from SG—including naringin, hesperetin 7-O-rutinoside, frangulin A, and 3″-p-Coumaroylprunin—exhibit close interactions with key targets regulating mitophagy, suggesting their pivotal roles in this process (Chen M. et al., 2023).

Shugan Xiaozhi (SG), composed of 15 botanical drugs, is commonly used to treat NAFLD. Studies demonstrate that SG alleviates HFD-induced hepatic inflammation and fibrosis in mice, suppresses ROS generation, enhances SOD, GSH, and CAT activities, and reduces MDA levels in a dose-dependent manner, thereby protecting mitochondrial structural and functional integrity in hepatocytes. The therapeutic effect of SG on NASH is closely associated with its regulation of BNIP3/BNIP3L-mediated mitophagy. Metabolites in SG—including naringin, hesperetin 7-O-rutinoside, frangulin A, and 3″-p-Coumaroylprunin—exhibit significant interactions with key mitophagy targets, thereby playing a central role in this mechanism (Chen M. et al., 2023).

5 Discussion

Immune dysregulation serves as a critical driver of NAFLD progression, making the maintenance of immune homeostasis an essential intervention strategy. GM regulates host immune balance through the gut-liver axis and participates in hepatic inflammation processes. Therefore, utilizing metabolites derived from botanical drugs to treat NAFLD through the GM-Immune Axis represents a promising strategy. As shown in Figure 4. However, its mechanisms remain incompletely elucidated and face multifaceted challenges.

FIGURE 4

GM is highly susceptible to environmental influences, resulting in significant research heterogeneity. This necessitates integrating multi-center large-sample cohorts with multi-omics data to enhance conclusion reliability. Organoid co-culture systems (Wang et al., 2024a) and CRISPR-based microbiota editing (Jin et al., 2022) provide novel approaches to overcome mechanistic bottlenecks. The former can simulate gut-liver axis immune interactions for target screening, while the latter enables precise identification of functional genes in GM and drug-action pathways.

The clinical efficacy evidence and translation of botanical drugs still face dilemmas. Current research predominantly focuses on basic mechanisms, with limited and low-quality clinical studies. These manifest experimental design flaws (e.g., inadequate sample size, suboptimal blinding, insufficient endpoint indicators, significant regional variations, and short follow-up periods), lax quality control, and lack of collaborative mechanisms, substantially diminishing the evidence level. Future efforts should initiate pilot experiments and observational studies to preliminarily evaluate efficacy, identify benefiting subpopulations, and define treatment endpoints, thereby providing foundations for subsequent large-scale RCTs. Studies must strictly adhere to the PICOTS framework, establish intelligent data centers, and follow international reporting standards (e.g., CONSORT, STRICTA) to advance the generation of high-quality clinical evidence.

The translation from basic research to clinical applications of botanical drugs also faces challenges. The multi-target characteristics result in unclear onset of action metabolites and dose-response relationships, while the lack of standardized preparation processes leads to inconsistent drug quality and irreproducible efficacy (Hu et al., 2019). Multidisciplinary platforms should be integrated to establish artificial intelligence-based metabolites screening and quality control systems, evaluate pharmacological effects using organoids/organs-on-chips, and ultimately develop a research paradigm featuring well-defined mechanisms, rigorous quality control, and quantifiable efficacy.

The safety of metabolites derived from botanical drugs also requires significant attention. Toxic side effects may be associated with exogenous contaminants (pesticides, heavy metals, mycotoxins), endogenous factors (origin, dosage, treatment duration, preparation processes), and individual variations (Gao et al., 2019). Current toxicological research remains limited, with unclear toxicity mechanisms and a lack of clinical risk warnings. Regulatory oversight of drug quality should be enhanced, toxicity evaluation systems improved, toxicity metabolites pre-screened using chemical structure warning databases, pharmacokinetic-toxicokinetic (PK-TK) models established through integrated in vivo and in vitro experiments, and novel technologies such as microfluidic chips, high-throughput screening, and systems toxicology introduced to develop more comprehensive safety evaluation standards.

In summary, elucidating the interaction targets among botanical drugs, GM, and immune dysregulation provides novel insights for NAFLD treatment, deepening our understanding of the gut-liver axis mechanism. Integrating mechanistic studies, clinical validation, and safety assessment holds promise for advancing systematic, standardized, and internationally recognized applications of botanical drugs in NAFLD treatment.

References

• 1

  AfrinR.ArumugamS.RahmanA.WahedM. I. I.KaruppagounderV.HarimaM.et al (2017). Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation. Int. Immunopharmacol.44, 174–182. 10.1016/j.intimp.2017.01.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  AgusA.ClémentK.SokolH. (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut70, 1174–1182. 10.1136/gutjnl-2020-323071

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  Al NabhaniZ.DietrichG.HugotJ.-P.BarreauF. (2017). Nod2: the intestinal gate keeper. PLoS Pathog.13, e1006177. 10.1371/journal.ppat.1006177

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  Al NabhaniZ.BerrebiD.Martinez-VinsonC.MontcuquetN.MadreC.RoyM.et al (2020). Nod2 protects the gut from experimental colitis spreading to small intestine. J. Crohns Colitis14, 669–679. 10.1093/ecco-jcc/jjz196

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  AlferinkL. J. M.RadjabzadehD.ErlerN. S.VojinovicD.Medina-GomezC.UitterlindenA. G.et al (2021). Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults. Hepatol. Balt. Md73, 968–982. 10.1002/hep.31417

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  AnD.OhS. F.OlszakT.NevesJ. F.AvciF. Y.Erturk-HasdemirD.et al (2014). Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell.156, 123–133. 10.1016/j.cell.2013.11.042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  AndersonH. A.RocheP. A. (2015). MHC class II association with lipid rafts on the antigen presenting cell surface. Biochim. Biophys. Acta1853, 775–780. 10.1016/j.bbamcr.2014.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  ArrenbergP.MaricicI.KumarV. (2011). Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology140, 646–655. 10.1053/j.gastro.2010.10.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  ArreseM.CabreraD.KalergisA. M.FeldsteinA. E. (2016). Innate immunity and inflammation in NAFLD/NASH. Dig. Dis. Sci.61, 1294–1303. 10.1007/s10620-016-4049-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  BalasubramanianI.GaoN. (2017). From sensing to shaping microbiota: insights into the role of NOD2 in intestinal homeostasis and progression of Crohn’s disease. Am. J. Physiol. Gastrointest. Liver Physiol.313, G7–G13. 10.1152/ajpgi.00330.2016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  BansalT.AlanizR. C.WoodT. K.JayaramanA. (2010). The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc. Natl. Acad. Sci. U. S. A.107, 228–233. 10.1073/pnas.0906112107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  BartneckM.ScheydaK. M.WarzechaK. T.RizzoL. Y.HittatiyaK.LueddeT.et al (2015). Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials37, 367–382. 10.1016/j.biomaterials.2014.10.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  BeisnerJ.Filipe RosaL.Kaden-VolynetsV.StolzerI.GüntherC.BischoffS. C. (2021). Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides. Front. Immunol.12, 678360. 10.3389/fimmu.2021.678360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  BernsmeierC.AlbanoE. (2017). Liver dendritic cells and NAFLD evolution: a remaining open issue. J. Hepatol.66, 1120–1122. 10.1016/j.jhep.2017.02.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  BhattacharjeeJ.KirbyM.SofticS.MilesL.Salazar-GonzalezR.-M.ShivakumarP.et al (2017). Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with Nonalcoholic steatohepatitis. Hepatol. Commun.1, 299–310. 10.1002/hep4.1041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  BiagioliM.CarinoA.CiprianiS.FrancisciD.MarchianòS.ScarpelliP.et al (2017). The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from Murine Colitis. J. Immunol. Balt. Md 1950199, 718–733. 10.4049/jimmunol.1700183

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  BieligH.RompikuntalP. K.DongreM.ZurekB.LindmarkB.RamstedtM.et al (2011). NOD-like receptor activation by outer membrane vesicles from Vibrio cholerae non-O1 non-O139 strains is modulated by the quorum-sensing regulator HapR. Infect. Immun.79, 1418–1427. 10.1128/IAI.00754-10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  BogdanosD. P.GaoB.GershwinM. E. (2013). Liver immunology. Compr. Physiol.3, 567–598. 10.1002/cphy.c120011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  BoursierJ.MuellerO.BarretM.MachadoM.FizanneL.Araujo-PerezF.et al (2016). The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatol. Balt. Md63, 764–775. 10.1002/hep.28356

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  BranzkN.LubojemskaA.HardisonS. E.WangQ.GutierrezM. G.BrownG. D.et al (2014). Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat. Immunol.15, 1017–1025. 10.1038/ni.2987

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 21

  BreuerD. A.PachecoM. C.WashingtonM. K.MontgomeryS. A.HastyA. H.KennedyA. J. (2020). CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol.318, G211–G224. 10.1152/ajpgi.00040.2019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  BrinkmannV.ReichardU.GoosmannC.FaulerB.UhlemannY.WeissD. S.et al (2004). Neutrophil extracellular traps kill bacteria. Science303, 1532–1535. 10.1126/science.1092385

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  CampbellC. L.YuR.LiF.ZhouQ.ChenD.QiC.et al (2019). Modulation of fat metabolism and gut microbiota by resveratrol on high-fat diet-induced obese mice. Diabetes Metab. Syndr. Obes. Targets Ther.12, 97–107. 10.2147/DMSO.S192228

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  CanforaE. E.JockenJ. W.BlaakE. E. (2015). Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol.11, 577–591. 10.1038/nrendo.2015.128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  CaoY.PanQ.CaiW.ShenF.ChenG.-Y.XuL.-M.et al (2016). Modulation of Gut Microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Arch. Iran. Med.19, 197–203.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 26

  CaoL.XuE.ZhengR.ZhangchenZ.ZhongR.HuangF.et al (2022). Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages. Chin. Med.17, 7. 10.1186/s13020-021-00559-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  CaoP.WangY.ZhangC.SullivanM. A.ChenW.JingX.et al (2023). Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy. J. Nutr. Biochem.120, 109414. 10.1016/j.jnutbio.2023.109414

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  CarpinoG.Del BenM.PastoriD.CarnevaleR.BarattaF.OveriD.et al (2020). Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatol. Balt. Md72, 470–485. 10.1002/hep.31056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  CavallariJ. F.BarraN. G.FoleyK. P.LeeA.DugganB. M.HenriksboB. D.et al (2020). Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice. Am. J. Physiol. Endocrinol. Metab.318, E579–E585. 10.1152/ajpendo.00033.2020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  ChackeleviciusC. M.GambaroS. E.TiribelliC.RossoN. (2016). Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J. Gastroenterol.22, 9096–9103. 10.3748/wjg.v22.i41.9096

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  Chávez-TalaveraO.TailleuxA.LefebvreP.StaelsB. (2017). Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic Fatty liver disease. Gastroenterology152, 1679–1694.e3. 10.1053/j.gastro.2017.01.055

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  CheQ.LuoT.ShiJ.HeY.XuD.-L. (2022). Mechanisms by which traditional Chinese medicines influence the intestinal flora and intestinal barrier. Front. Cell. Infect. Microbiol.12, 863779. 10.3389/fcimb.2022.863779

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  ChenS.ZhaoX.RanL.WanJ.WangX.QinY.et al (2015). Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver47, 226–232. 10.1016/j.dld.2014.11.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  ChenM.HouP.ZhouM.RenQ.WangX.HuangL.et al (2020). Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system. Clin. Nutr. Edinb. Scotl.39, 1264–1275. 10.1016/j.clnu.2019.05.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  ChenJ.LiX.GeC.MinJ.WangF. (2022). The multifaceted role of ferroptosis in liver disease. Cell. Death Differ.29, 467–480. 10.1038/s41418-022-00941-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  ChenD.XiongJ.ChenG.ZhangZ.LiuY.XuJ.et al (2023a). Comparing the influences of metformin and berberine on the intestinal microbiota of rats with Nonalcoholic steatohepatitis. Vivo Athens Greece37, 2105–2127. 10.21873/invivo.13308

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  ChenY.HaoZ.ZhaoH.DuanX.JiaD.LiK.et al (2023b). Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan metabolites. J. Sci. Food Agric.103, 1464–1473. 10.1002/jsfa.12242

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  ChenM.HuangF.ChenB.KangJ.YaoY.LiuaM.et al (2023c). A classical herbal formula alleviates high-fat diet induced nonalcoholic steatohepatitis (NASH) via targeting mitophagy to rehabilitate dysfunctional mitochondria, validated by UPLC-HRMS identification combined with in vivo experiment. Biomed. Pharmacother. Biomedecine Pharmacother.168, 115831. 10.1016/j.biopha.2023.115831

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  ChiangY.-Y.ChaoJ. C.-J. (2018). Olive oil combined with Lycium barbarum polysaccharides attenuates liver apoptosis and inflammation induced by carbon tetrachloride in rats. J. Funct. Foods48, 329–336. 10.1016/j.jff.2018.07.029

  • CrossRef
  • Google Scholar

• 40

  ChungE. Y.KimB. H.HongJ.-T.LeeC.-K.AhnB.NamS.-Y.et al (2011). Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J. Nutr. Biochem.22, 902–909. 10.1016/j.jnutbio.2010.07.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  ConnollyM. K.BedrosianA. S.Mallen-St ClairJ.MitchellA. P.IbrahimJ.StroudA.et al (2009). In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J. Clin. Investig.119, 3213–3225. 10.1172/JCI37581

  • CrossRef
  • Google Scholar

• 42

  CorbinK. D.ZeiselS. H. (2012). Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr. Opin. Gastroenterol.28, 159–165. 10.1097/MOG.0b013e32834e7b4b

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  CrespoM.NikolicI.MoraA.RodríguezE.Leiva-VegaL.Pintor-ChocanoA.et al (2023). Myeloid p38 activation maintains macrophage-liver crosstalk and BAT thermogenesis through IL-12-FGF21 axis. Hepatol. Balt. Md77, 874–887. 10.1002/hep.32581

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  CsakT.VelayudhamA.HritzI.PetrasekJ.LevinI.LippaiD.et al (2011). Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol.300, G433–G441. 10.1152/ajpgi.00163.2009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  CynthiaJ.FrankT. (2016). Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell. Mol. Immunol.13, 316–327. 10.1038/cmi.2015.104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  DaemenS.GainullinaA.KalugotlaG.HeL.ChanM. M.BealsJ. W.et al (2021). Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell. Rep.34, 108626. 10.1016/j.celrep.2020.108626

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  De BruynM.VermeireS. (2017). NOD2 and bacterial recognition as therapeutic targets for Crohn’s disease. Expert Opin. Ther. Targets21, 1123–1139. 10.1080/14728222.2017.1397627

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  DeczkowskaA.DavidE.RamadoriP.PfisterD.SafranM.LiB.et al (2021). XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat. Med.27, 1043–1054. 10.1038/s41591-021-01344-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  DengM.QuF.ChenL.LiuC.ZhangM.RenF.et al (2020). SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J. Endocrinol.245, 425–437. 10.1530/JOE-20-0018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  DengC.-J.LoT.-H.ChanK.-Y.LiX.WuM.-Y.XiangZ.et al (2022). Role of B Lymphocytes in the Pathogenesis of NAFLD: a 2022 update. Int. J. Mol. Sci.23, 12376. 10.3390/ijms232012376

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  DharancyS.Body-MalapelM.LouvetA.BerrebiD.GantierE.GossetP.et al (2010). Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. Gastroenterology138, 1546–1556.e15565. 10.1053/j.gastro.2009.12.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  DiehlA. M.DayC. (2017). Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med.377, 2063–2072. 10.1056/NEJMra1503519

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  DingY.YanY.PengY.ChenD.MiJ.LuL.et al (2019). In vitro digestion under simulated saliva, gastric and small intestinal conditions and fermentation by human gut microbiota of polysaccharides from the fruits of Lycium barbarum. Int. J. Biol. Macromol.125, 751–760. 10.1016/j.ijbiomac.2018.12.081

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  DoddD.SpitzerM. H.Van TreurenW.MerrillB. D.HryckowianA. J.HigginbottomS. K.et al (2017). A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature551, 648–652. 10.1038/nature24661

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  DornerH.StolzerI.MattnerJ.KaminskiS.LeistlS.EdrichL.-M.et al (2024). Gut pathobiont-derived outer membrane vesicles drive liver inflammation and fibrosis in primary sclerosing cholangitis-associated inflammatory bowel disease. Gastroenterology167, 1183–1197.e16. 10.1053/j.gastro.2024.06.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  DuJ.ZhangJ.ChenX.ZhangS.ZhangC.LiuH.et al (2022). Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients. Clin. Res. Hepatol. Gastroenterol.46, 101697. 10.1016/j.clinre.2021.101697

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  DudekM.PfisterD.DonakondaS.FilpeP.SchneiderA.LaschingerM.et al (2021). Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature592, 444–449. 10.1038/s41586-021-03233-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  DywickiJ.Buitrago-MolinaL. E.NoyanF.Davalos-MisslitzA. C.Hupa-BreierK. L.LieberM.et al (2022). The detrimental role of regulatory T cells in nonalcoholic steatohepatitis. Hepatol. Commun.6, 320–333. 10.1002/hep4.1807

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  EissaL. A.KenawyH. I.El-KarefA.ElsherbinyN. M.El-MihiK. A. (2018). Antioxidant and anti-inflammatory activities of berberine attenuate hepatic fibrosis induced by thioacetamide injection in rats. Chem. Biol. Interact.294, 91–100. 10.1016/j.cbi.2018.08.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  ExleyM. A.KozielM. J. (2004). To be or not to be NKT: natural killer T cells in the liver. Hepatol. Balt. Md40, 1033–1040. 10.1002/hep.20433

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  FaP.KeB. G.DupreA.TsungA.ZhangH. (2023). The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease. Front. Immunol.14, 1292679. 10.3389/fimmu.2023.1292679

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  FanH.CookJ. A. (2004). Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res.10, 71–84. 10.1179/096805104225003997

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  FanY.PuY.XuX.YangJ. (2025a). Benefit of Lycium barbarum polysaccharide supplementation in patients with nonalcoholic fatty liver disease: a pre-post study. Nutr. Health, 02601060251357979. 10.1177/02601060251357979

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  FanY.YangC.PanJ.YeW.ZhangJ.ZengR.et al (2025b). A new target for curcumin in the treatment of non-alcoholic fatty liver disease: the FTO protein. Int. J. Biol. Macromol.319, 145642. 10.1016/j.ijbiomac.2025.145642

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  FeingoldK. R.MoserA.ShigenagaJ. K.GrunfeldC. (2014). Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages. J. Lipid Res.55, 2501–2508. 10.1194/jlr.M050955

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  FichtX.IannaconeM. (2020). Immune surveillance of the liver by T cells. Sci. Immunol.5, eaba2351. 10.1126/sciimmunol.aba2351

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  FiorucciS.ZampellaA.RicciP.DistruttiE.BiagioliM. (2022). Immunomodulatory functions of FXR. Mol. Cell. Endocrinol.551, 111650. 10.1016/j.mce.2022.111650

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  FizanneL.VillardA.BenabbouN.RecoquillonS.SoletiR.DelageE.et al (2023). Faeces-derived extracellular vesicles participate in the onset of barrier dysfunction leading to liver diseases. J. Extracell. Vesicles12, e12303. 10.1002/jev2.12303

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  Flores-GuerreroJ. L.PostA.van DijkP. R.ConnellyM. A.GarciaE.NavisG.et al (2021). Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. Liver Int. Off. J. Int. Assoc. Study Liver41, 2371–2382. 10.1111/liv.14963

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  FolcoE. J.MawsonT. L.VrommanA.Bernardes-SouzaB.FranckG.PerssonO.et al (2018). Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through Interleukin-1α and Cathepsin G. Arterioscler. Thromb. Vasc. Biol.38, 1901–1912. 10.1161/ATVBAHA.118.311150

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  FurusawaY.ObataY.FukudaS.EndoT. A.NakatoG.TakahashiD.et al (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature504, 446–450. 10.1038/nature12721

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  GaoY.LiangA.FanX.HuL.HaoF.LiY. (2019). Safety research in traditional Chinese medicine: methods, applications, and outlook. Engineering5, 76–82. 10.1016/j.eng.2018.11.019

  • CrossRef
  • Google Scholar

• 73

  GaoL.-L.MaJ.-M.FanY.-N.ZhangY.-N.GeR.TaoX.-J.et al (2021). Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int. J. Biol. Macromol.183, 1379–1392. 10.1016/j.ijbiomac.2021.05.066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  GaoW.ZhangL.WuJ.XuY.QiS.LiuW.et al (2023). Extraction, characterization, and anti-nonalcoholic steatohepatitis activity of a (1,3) (1,6)-β-D-glucan from the Polyporus umbellatus (Pers.) fries. Int. J. Biol. Macromol.230, 123252. 10.1016/j.ijbiomac.2023.123252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  GavzyS. J.KensiskiA.LeeZ. L.MongodinE. F.MaB.BrombergJ. S. (2023). Bifidobacterium mechanisms of immune modulation and tolerance. Gut Microbes15, 2291164. 10.1080/19490976.2023.2291164

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  GinhouxF.YalinA.DutertreC. A.AmitI. (2022). Single-cell immunology: past, present, and future. Immunity55, 393–404. 10.1016/j.immuni.2022.02.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  GoettelJ. A.GandhiR.KenisonJ. E.YesteA.MurugaiyanG.SambanthamoorthyS.et al (2016). AHR activation is protective against colitis driven by T cells in humanized mice. Cell. Rep.17, 1318–1329. 10.1016/j.celrep.2016.09.082

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  GolabiP.PaikJ.ReddyR.BugianesiE.TrimbleG.YounossiZ. M. (2019). Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol.19, 56. 10.1186/s12876-019-0972-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  GomesM. T.CamposP. C.PereiraG. de S.BartholomeuD. C.SplitterG.OliveiraS. C. (2016). TLR9 is required for MAPK/NF-κB activation but does not cooperate with TLR2 or TLR6 to induce host resistance to Brucella abortus. J. Leukoc. Biol.99, 771–780. 10.1189/jlb.4A0815-346R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  GuL.MengR.TangY.ZhaoK.LiangF.ZhangR.et al (2019). Toll-Like receptor 4 signaling licenses the cytosolic transport of lipopolysaccharide from bacterial outer membrane vesicles. Shock Augusta Ga51, 256–265. 10.1097/SHK.0000000000001129

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  GuarigliaM.SabaF.RossoC.BugianesiE. (2023). Molecular mechanisms of curcumin in the pathogenesis of Metabolic Dysfunction associated steatotic liver disease. Nutrients15, 5053. 10.3390/nu15245053

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  GuilliamsM.ScottC. L. (2022). Liver macrophages in health and disease. Immunity55, 1515–1529. 10.1016/j.immuni.2022.08.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  GuoC.XieS.ChiZ.ZhangJ.LiuY.ZhangL.et al (2016a). Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity45, 802–816. 10.1016/j.immuni.2016.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  GuoT.WooS.-L.GuoX.LiH.ZhengJ.BotchlettR.et al (2016b). Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci. Rep.6, 22612. 10.1038/srep22612

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  HakhamaneshiM. S.AbdolahiA.VahabzadehZ.AbdiM.AndalibiP. (2021). Toll-Like receptor 4: a macrophage cell surface receptor is activated by Trimethylamine-N-Oxide. Cell. J.23, 516–522. 10.22074/cellj.2021.7849

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  HayashiK.TauraM.IwasakiA. (2018). The interaction between IKKα and LC3 promotes type I interferon production through the TLR9-containing LAPosome. Sci. Signal.11, eaan4144. 10.1126/scisignal.aan4144

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  HeB.WuL.XieW.ShaoY.JiangJ.ZhaoZ.et al (2017). The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol.18, 33. 10.1186/s12865-017-0215-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  HeY.ChenX.LiY.LiangY.HongT.YangJ.et al (2024). Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial. Am. J. Clin. Nutr.120, 66–79. 10.1016/j.ajcnut.2024.05.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  HenningJ. R.GraffeoC. S.RehmanA.FallonN. C.ZambirinisC. P.OchiA.et al (2013). Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatol. Balt. Md58, 589–602. 10.1002/hep.26267

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  HesseM.ModolellM.La FlammeA. C.SchitoM.FuentesJ. M.CheeverA. W.et al (2001). Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J. Immunol. Balt. Md 1950167, 6533–6544. 10.4049/jimmunol.167.11.6533

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  HeymannF.TrautweinC.TackeF. (2009). Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm. Allergy Drug Targets8, 307–318. 10.2174/187152809789352230

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  HongT.JiangX.ZouJ.YangJ.ZhangH.MaiH.et al (2022). Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice. J. Nutr. Biochem.109, 109103. 10.1016/j.jnutbio.2022.109103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  HosseinkhaniF.HeinkenA.ThieleI.LindenburgP. W.HarmsA. C.HankemeierT. (2021). The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases. Gut Microbes13, 1–22. 10.1080/19490976.2021.1882927

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  HuZ.-Q.XianJ.-C.ChuS.-C.WangJ.-Y.ShenL.ZhangL.et al (2019). Development status and research strategy of traditional Chinese medicine temporary prescription preparation technology. Zhongguo Zhong Yao Za Zhi Zhongguo Zhongyao Zazhi China J. Chin. Mat. Medica44, 28–33. 10.19540/j.cnki.cjcmm.20181107.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  HuH.LinA.KongM.YaoX.YinM.XiaH.et al (2020). Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J. Gastroenterol.55, 142–158. 10.1007/s00535-019-01649-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  HuY.-L.MaQ.DongX.KongY.CaiJ.LiJ.et al (2023). Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseases. Front. Nutr.10, 1107551. 10.3389/fnut.2023.1107551

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  HuangL.RaoQ.WangC.MouY.ZhengX.HuE.et al (2024). Multi-omics joint analysis reveals that the Miao medicine Yindanxinnaotong formula attenuates non-alcoholic fatty liver disease. Phytomedicine Int. J. Phytother. Phytopharm.135, 156026. 10.1016/j.phymed.2024.156026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  HuangM.JiQ.HuangH.WangX.WangL. (2025a). Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes17, 2486519. 10.1080/19490976.2025.2486519

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  HuangY.XieY.ZhangY.LiuZ.JiangW.YeY.et al (2025b). Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC. Mol. Cancer24, 177. 10.1186/s12943-025-02370-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  HubyT.GautierE. L. (2022). Immune cell-mediated features of non-alcoholic steatohepatitis. Nat. Rev. Immunol.22, 429–443. 10.1038/s41577-021-00639-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  HungJ.-T.HuangJ.-R.YuA. L. (2017). Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J. Biomed. Sci.24, 22. 10.1186/s12929-017-0325-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  JaneiroM. H.RamírezM. J.MilagroF. I.MartínezJ. A.SolasM. (2018). Implication of trimethylamine N-Oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients10, 1398. 10.3390/nu10101398

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  JdS.BlC. (2021). Modulation of macrophage phenotype to treat liver fibrosis-current approaches and future possibilities. Adv. Pharmacol. San. Diego Calif.91, 213–228. 10.1016/bs.apha.2021.03.001

  • CrossRef
  • Google Scholar

• 104

  JenneC. N.KubesP. (2013). Immune surveillance by the liver. Nat. Immunol.14, 996–1006. 10.1038/ni.2691

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  JiY.YinY.SunL.ZhangW. (2020). The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement. Int. J. Mol. Sci.21, 3066. 10.3390/ijms21093066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  JiangY.-H.WangL.ChenW.-D.DuanY.-T.SunM.-J.HuangJ.-J.et al (2022). Poria cocos polysaccharide prevents alcohol-induced hepatic injury and inflammation by repressing oxidative stress and gut leakiness. Front. Nutr.9, 963598. 10.3389/fnut.2022.963598

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  JiangL.YiR.ChenH.WuS. (2025). Quercetin alleviates metabolic-associated fatty liver disease by tuning hepatic lipid metabolism, oxidative stress and inflammation. Anim. Biotechnol.36, 2442351. 10.1080/10495398.2024.2442351

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  JiaoJ.SastreD.FielM. I.LeeU. E.Ghiassi-NejadZ.GinhouxF.et al (2012). Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatol. Balt. Md55, 244–255. 10.1002/hep.24621

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  JinW.-B.LiT.-T.HuoD.QuS.LiX. V.ArifuzzamanM.et al (2022). Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome. Cell.185, 547–562.e22. 10.1016/j.cell.2021.12.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  JinR.NeufeldL.McGahaT. L. (2025). Linking macrophage metabolism to function in the tumor microenvironment. Nat. Cancer6, 239–252. 10.1038/s43018-025-00909-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  JingZ.JingyiJ.YueL.ZhangS.LiF.CuiJ.et al (2025). Yinchen-Gancao decoction ameliorated NASH in mice by reducing hepatic lipid accumulation, inhibiting hepatic inflammatory and endoplasmic reticulum stress. J. Ethnopharmacol.341, 119318. 10.1016/j.jep.2025.119318

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  JosefowiczS. Z.LuL.-F.RudenskyA. Y. (2012). Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol.30, 531–564. 10.1146/annurev.immunol.25.022106.141623

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  Juárez-VerdayesM. A.Rodríguez-MartínezS.Cancino-DiazM. E.Cancino-DiazJ. C. (2013). Peptidoglycan and muramyl dipeptide from Staphylococcus aureus induce the expression of VEGF-A in human limbal fibroblasts with the participation of TLR2-NFκB and NOD2-EGFR. Graefes Arch. Clin. Exp. Ophthalmol. Albr. Von. Graefes Arch. Klin. Exp. Ophthalmol.251, 53–62. 10.1007/s00417-012-2130-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  KechagiasS.NasrP.BlomdahlJ.EkstedtM. (2020). Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism111S, 154183. 10.1016/j.metabol.2020.154183

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  Keestra-GounderA. M.TsolisR. M. (2017). NOD1 and NOD2: beyond peptidoglycan sensing. Trends Immunol.38, 758–767. 10.1016/j.it.2017.07.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  KeitelV.ReinehrR.GatsiosP.RupprechtC.GörgB.SelbachO.et al (2007). The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatol. Balt. Md45, 695–704. 10.1002/hep.21458

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  KodaY.TerataniT.ChuP.-S.HagiharaY.MikamiY.HaradaY.et al (2021). CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. Nat. Commun.12, 4474. 10.1038/s41467-021-24734-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  KongL.ZhaoQ.JiangX.HuJ.JiangQ.ShengL.et al (2024). Trimethylamine N-oxide impairs β-cell function and glucose tolerance. Nat. Commun.15, 2526. 10.1038/s41467-024-46829-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  KruegerJ. M.PappenheimerJ. R.KarnovskyM. L. (1982). The composition of sleep-promoting factor isolated from human urine. J. Biol. Chem.257, 1664–1669. 10.1016/s0021-9258(19)68088-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  KwanS.-Y.JiaoJ.JoonA.WeiP.PettyL. E.BelowJ. E.et al (2022). Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatol. Balt. Md75, 955–967. 10.1002/hep.32197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  LandfriedK.ZhuW.WaldhierM. C.SchulzU.AmmerJ.HollerB.et al (2011). Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood118, 6971–6974. 10.1182/blood-2011-06-357814

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  LeeG.YouH. J.BajajJ. S.JooS. K.YuJ.ParkS.et al (2020). Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in Non-obese NAFLD. Nat. Commun.11, 4982. 10.1038/s41467-020-18754-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  LeiJ.-Q.XieQ.-L.LiQ.-P.QinS.-Y.WuJ.-H.JiangH.-X.et al (2025). Resveratrol alleviates liver fibrosis by targeting cross-talk between TLR2/MyD88/ERK and NF-κB/NLRP3 inflammasome pathways in macrophages. J. Biochem. Mol. Toxicol.39, e70208. 10.1002/jbt.70208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  LeungH.LongX.NiY.QianL.NychasE.SiliceoS. L.et al (2022). Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci. Transl. Med.14, eabk0855. 10.1126/scitranslmed.abk0855

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  LiL.ZhangQ.PengJ.JiangC.ZhangY.ShenL.et al (2015). Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage. Biochem. Biophys. Res. Commun.467, 841–846. 10.1016/j.bbrc.2015.10.056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  LiD.ZhengJ.HuY.HouH.HaoS.LiuN.et al (2017). Amelioration of intestinal barrier dysfunction by berberine in the treatment of nonalcoholic Fatty liver disease in rats. Pharmacogn. Mag.13, 677–682. 10.4103/pm.pm_584_16

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  LiF.YeJ.ShaoC.ZhongB. (2021a). Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis.20, 22. 10.1186/s12944-021-01440-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  LiS.YouJ.WangZ.LiuY.WangB.DuM.et al (2021b). Curcumin alleviates high-fat diet-induced hepatic steatosis and obesity in association with modulation of gut microbiota in mice. Food Res. Int. ott. Ont.143, 110270. 10.1016/j.foodres.2021.110270

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  LiD.-D.MaJ.-M.LiM.-J.GaoL.-L.FanY.-N.ZhangY.-N.et al (2022). Supplementation of Lycium barbarum polysaccharide combined with aerobic exercise ameliorates high-fat-induced nonalcoholic steatohepatitis via AMPK/PPARα/PGC-1α pathway. Nutrients14, 3247. 10.3390/nu14153247

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  LiN.CuiC.XuJ.MiM.WangJ.QinY. (2024a). Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial. Am. J. Clin. Nutr.120, 507–517. 10.1016/j.ajcnut.2024.07.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  LiX.ChenW.RenJ.GaoX.ZhaoY.SongT.et al (2024b). Effects of curcumin on non-alcoholic fatty liver disease: a scientific metrogy study. Phytomedicine Int. J. Phytother. Phytopharm.123, 155241. 10.1016/j.phymed.2023.155241

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  LiangW.ZhouK.JianP.ChangZ.ZhangQ.LiuY.et al (2021). Ginsenosides improve nonalcoholic Fatty liver disease via integrated regulation of Gut Microbiota, inflammation and energy homeostasis. Front. Pharmacol.12, 622841. 10.3389/fphar.2021.622841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  LiuJ.LiuY.HuangC.HeC.YangT.RenR.et al (2025a). Quercetin-Driven Akkermansia Muciniphila alleviates obesity by modulating bile acid metabolism via an ILA/m6A/CYP8B1 signaling. Adv. Sci. Weinh. Baden-Wurtt. Ger.12, e2412865. 10.1002/advs.202412865

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  LiuW.YuL.ChenQ.ZhangC.WangL.YuN.et al (2025b). Poria cocos polysaccharides alleviate obesity-related adipose tissue insulin resistance via gut microbiota-derived short-chain fatty acids activation of FGF21/PI3K/AKT signaling. Food Res. Int. ott. Ont.215, 116671. 10.1016/j.foodres.2025.116671

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  LiuW.ZhouX.XiaoL.HuangX.ChangD.ZhongX.et al (2025c). The gut microbiota-mediated ferroptosis pathway: a key mechanism of ginsenoside Rd against metabolism-associated fatty liver disease. Chin. Med.20, 83. 10.1186/s13020-025-01121-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  LiuY.ZhouF.ZhaoH.SongJ.SongM.ZhuJ.et al (2025d). Dimeric guaianolide sesquiterpenoids from the flowers of Chrysanthemum indicum ameliorate hepatic steatosis through mitigating SIRT1-mediated lipid accumulation and ferroptosis. J. Adv. Res.S2090-1232 (24), 00625–00628. 10.1016/j.jare.2024.12.047

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  LlopisM.CassardA. M.WrzosekL.BoschatL.BruneauA.FerrereG.et al (2016). Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut65, 830–839. 10.1136/gutjnl-2015-310585

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  LoombaR.SeguritanV.LiW.LongT.KlitgordN.BhattA.et al (2017). Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic Fatty liver disease. Cell. Metab.25, 1054–1062.e5. 10.1016/j.cmet.2017.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  LoombaR.FriedmanS. L.ShulmanG. I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell.184, 2537–2564. 10.1016/j.cell.2021.04.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  Lukacs-KornekV.SchuppanD. (2013). Dendritic cells in liver injury and fibrosis: shortcomings and promises. J. Hepatol.59, 1124–1126. 10.1016/j.jhep.2013.05.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  MantovaniA.SicaA.SozzaniS.AllavenaP.VecchiA.LocatiM. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol.25, 677–686. 10.1016/j.it.2004.09.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  MaricicI.ShengH.MarreroI.SekiE.KisselevaT.ChaturvediS.et al (2015). Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatol. Balt. Md61, 1357–1369. 10.1002/hep.27632

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  MarreroI.WareR.KumarV. (2015). Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer. Front. Immunol.6, 316. 10.3389/fimmu.2015.00316

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  MarreroI.MaricicI.FeldsteinA. E.LoombaR.SchnablB.Rivera-NievesJ.et al (2018). Complex network of NKT cell subsets controls immune homeostasis in liver and gut. Front. Immunol.9, 2082. 10.3389/fimmu.2018.02082

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  MartinezF. O.GordonS.LocatiM.MantovaniA. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. Balt. Md 1950177, 7303–7311. 10.4049/jimmunol.177.10.7303

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  Martínez-ChantarM. L.DelgadoT. C.BerazaN. (2021). Revisiting the role of natural killer cells in non-alcoholic fatty liver disease. Front. Immunol.12, 640869. 10.3389/fimmu.2021.640869

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  MathewsS.FengD.MaricicI.JuC.KumarV.GaoB. (2016). Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. Cell. Mol. Immunol.13, 206–216. 10.1038/cmi.2015.06

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  MatsumotoK.IchimuraM.TsuneyamaK.MoritokiY.TsunashimaH.OmagariK.et al (2017). Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PloS One12, e0175406. 10.1371/journal.pone.0175406

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  MeliR.Mattace RasoG.CalignanoA. (2014). Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol.5, 177. 10.3389/fimmu.2014.00177

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  Méndez-SánchezN.Valencia-RodríguezA.Coronel-CastilloC.Vera-BarajasA.Contreras-CarmonaJ.Ponciano-RodríguezG.et al (2020). The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis. Ann. Transl. Med.8, 400. 10.21037/atm.2020.02.184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  MerouehS. O.BenczeK. Z.HesekD.LeeM.FisherJ. F.StemmlerT. L.et al (2006). Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc. Natl. Acad. Sci. U. S. A.103, 4404–4409. 10.1073/pnas.0510182103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  MinB. H.DeviS.KwonG. H.GuptaH.JeongJ.-J.SharmaS. P.et al (2024). Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes16, 2307568. 10.1080/19490976.2024.2307568

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  Moreno-FernandezM. E.GilesD. A.OatesJ. R.ChanC. C.DamenM. S. M. A.DollJ. R.et al (2021). PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. Cell. Metab.33, 1187–1204.e9. 10.1016/j.cmet.2021.04.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  MouriesJ.BresciaP.SilvestriA.SpadoniI.SorribasM.WiestR.et al (2019). Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J. Hepatol.71, 1216–1228. 10.1016/j.jhep.2019.08.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  MridhaA. R.HaczeyniF.YehM. M.HaighW. G.IoannouG. N.BarnV.et al (2017). TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. Clin. Sci. Lond. Engl. 1979131, 2145–2159. 10.1042/CS20160838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  NatiM.HaddadD.BirkenfeldA. L.KochC. A.ChavakisT.ChatzigeorgiouA. (2016). The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev. Endocr. Metab. Disord.17, 29–39. 10.1007/s11154-016-9339-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  NguM. H.NorhayatiM. N.RosnaniZ.ZulkifliM. M. (2022). Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: a systematic review and meta-analysis. Complement. Ther. Med.68, 102843. 10.1016/j.ctim.2022.102843

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  NguyenN. T.KimuraA.NakahamaT.ChinenI.MasudaK.NoharaK.et al (2010). Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A.107, 19961–19966. 10.1073/pnas.1014465107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  NianF.ChenY.XiaQ.ZhuC.WuL.LuX. (2024). Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance. Int. Immunopharmacol.142, 113173. 10.1016/j.intimp.2024.113173

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  NiazpourF.MeshkaniR. (2025). Unlocking the therapeutic potential of autophagy modulation by natural products in tackling non-alcoholic fatty liver disease. Phytother. Res.PTR, 2357–2373. 10.1002/ptr.8463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  NicolasG. R.ChangP. V. (2019). Deciphering the chemical lexicon of host-gut microbiota interactions. Trends Pharmacol. Sci.40, 430–445. 10.1016/j.tips.2019.04.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  NighotM.Al-SadiR.GuoS.RawatM.NighotP.WattersonM. D.et al (2017). Lipopolysaccharide-Induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/Myeloid differentiation primary response 88 (MyD88) activation of Myosin Light chain kinase expression. Am. J. Pathol.187, 2698–2710. 10.1016/j.ajpath.2017.08.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  NimmerjahnA.KirchhoffF.HelmchenF. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science308, 1314–1318. 10.1126/science.1110647

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  PallettL. J.SwadlingL.DinizM.MainiA. A.SchwabenlandM.GasullA. D.et al (2023). Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS. Nature614, 334–342. 10.1038/s41586-022-05645-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  PanchalS. K.PoudyalH.BrownL. (2012). Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr.142, 1026–1032. 10.3945/jn.111.157263

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  PappoI.BercovierH.BerryE. M.HavivY.GallilyR.FreundH. R. (1992). Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. JPEN J. Parenter. Enter. Nutr.16, 529–532. 10.1177/0148607192016006529

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  ParkJ.KimM.KangS. G.JannaschA. H.CooperB.PattersonJ.et al (2015). Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol.8, 80–93. 10.1038/mi.2014.44

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  PeiselerM.SchwabeR.HampeJ.KubesP.HeikenwälderM.TackeF. (2022). Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J. Hepatol.77, 1136–1160. 10.1016/j.jhep.2022.06.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  PengL.HeZ.ChenW.HolzmanI. R.LinJ. (2007). Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr. Res.61, 37–41. 10.1203/01.pdr.0000250014.92242.f3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  PengY.LiY.HeY.WeiQ.XieQ.ZhangL.et al (2018). The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review. Expert Rev. Gastroenterol. Hepatol.12, 503–513. 10.1080/17474124.2018.1463158

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  PfisterD.NúñezN. G.PinyolR.GovaereO.PinterM.SzydlowskaM.et al (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature592, 450–456. 10.1038/s41586-021-03362-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  PolsT. W. H.NomuraM.HarachT.Lo SassoG.OosterveerM. H.ThomasC.et al (2011). TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell. Metab.14, 747–757. 10.1016/j.cmet.2011.11.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  PorrasD.NistalE.Martínez-FlórezS.Pisonero-VaqueroS.OlcozJ. L.JoverR.et al (2017). Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic. Biol. Med.102, 188–202. 10.1016/j.freeradbiomed.2016.11.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  PowellD. N.SwimmA.SonowalR.BretinA.GewirtzA. T.JonesR. M.et al (2020). Indoles from the commensal microbiota act via the AHR and IL-10 to tune the cellular composition of the colonic epithelium during aging. Proc. Natl. Acad. Sci. U. S. A.117, 21519–21526. 10.1073/pnas.2003004117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  PowellE. E.WongV. W.-S.RinellaM. (2021). Non-alcoholic fatty liver disease. Lancet lond. Engl.397, 2212–2224. 10.1016/S0140-6736(20)32511-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  ProcházkováN.LaursenM. F.La BarberaG.TsekitsidiE.JørgensenM. S.RasmussenM. A.et al (2024). Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat. Microbiol.9, 3210–3225. 10.1038/s41564-024-01856-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  QiuJ.ChenL.ZhangL.XuF.ZhangC.RenG.et al (2023). Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy. Phytomedicine Int. J. Phytother. Phytopharm.121, 155111. 10.1016/j.phymed.2023.155111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  Quesada-VázquezS.BoneC.SahaS.TrigueroI.Colom-PellicerM.AragonèsG.et al (2022). Microbiota dysbiosis and gut barrier dysfunction associated with non-alcoholic fatty liver disease are modulated by a specific metabolic cofactors’ combination. Int. J. Mol. Sci.23, 13675. 10.3390/ijms232213675

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  RawatK.ShrivastavaA. (2022). Neutrophils as emerging protagonists and targets in chronic inflammatory diseases. Inflamm. Res. Off. J. Eur. Histamine Res. Soc. Al71, 1477–1488. 10.1007/s00011-022-01627-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  ReidD. T.ReyesJ. L.McDonaldB. A.VoT.ReimerR. A.EksteenB. (2016). Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation. PloS One11, e0159524. 10.1371/journal.pone.0159524

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  RenG.LinY.FuY.LiuF.WangR.ZhangC.et al (2025a). Multi-omics joint analysis: pachymic acid ameliorated non-alcoholic fatty liver disease by regulating gut microbiota. Food Res. Int. ott. Ont.209, 116178. 10.1016/j.foodres.2025.116178

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  RenG.LinY.QiuJ.ZhangC.ChenL.ZhuL.et al (2025b). Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα. Front. Pharmacol.16, 1554850. 10.3389/fphar.2025.1554850

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  RothhammerV.QuintanaF. J. (2019). The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol.19, 184–197. 10.1038/s41577-019-0125-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  SakaH. A.ValdiviaR. (2012). Emerging roles for lipid droplets in immunity and host-pathogen interactions. Annu. Rev. Cell. Dev. Biol.28, 411–437. 10.1146/annurev-cellbio-092910-153958

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  SamQ. H.LingH.YewW. S.TanZ.RavikumarS.ChangM. W.et al (2021). The divergent immunomodulatory effects of short chain fatty acids and medium chain fatty acids. Int. J. Mol. Sci.22, 6453. 10.3390/ijms22126453

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  SarfrazM. H.ShahidA.AsgharS.AslamB.AshfaqU. A.RazaH.et al (2022). Personalized nutrition, microbiota, and metabolism: a triad for eudaimonia. Front. Mol. Biosci.9, 1038830. 10.3389/fmolb.2022.1038830

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  SavageT. M.FortsonK. T.de Los Santos-AlexisK.Oliveras-AlsinaA.RouanneM.RaeS. S.et al (2024). Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis. Immunity57, 303–318.e6. 10.1016/j.immuni.2024.01.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  SchnablB. (2013). Linking intestinal homeostasis and liver disease. Curr. Opin. Gastroenterol.29, 264–270. 10.1097/MOG.0b013e32835ff948

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  SchneiderK. M.MohsA.GuiW.GalvezE. J. C.CandelsL. S.HoenickeL.et al (2022). Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat. Commun.13, 3964. 10.1038/s41467-022-31312-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  ShaoJ.GeT.TangC.WangG.PangL.ChenZ. (2022). Synergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis. Inflamm. Res. Off. J. Eur. Histamine Res. Soc. Al71, 1389–1401. 10.1007/s00011-022-01629-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  ShiY.GauerJ. S.BakerS. R.PhilippouH.ConnellS. D.AriënsR. a. S. (2021). Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro. Sci. Rep.11, 1718. 10.1038/s41598-021-81268-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  ShiY.ChenJ.QuD.SunQ.YuY.ZhangH.et al (2024). Ginsenoside Rg5 activates the LKB1/AMPK/mTOR signaling pathway and modifies the gut Microbiota to alleviate nonalcoholic Fatty liver disease induced by a high-fat diet. Nutrients16, 842. 10.3390/nu16060842

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  ShimadaY.KinoshitaM.HaradaK.MizutaniM.MasahataK.KayamaH.et al (2013). Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. PloS One8, e80604. 10.1371/journal.pone.0080604

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  ShimizuH.MasujimaY.UshirodaC.MizushimaR.TairaS.Ohue-KitanoR.et al (2019). Dietary short-chain fatty acid intake improves the hepatic metabolic condition via FFAR3. Sci. Rep.9, 16574. 10.1038/s41598-019-53242-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  ShresthaS.HongC.-W. (2023). Extracellular mechanisms of neutrophils in immune cell crosstalk. Immune Netw.23, e38. 10.4110/in.2023.23.e38

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  SongQ.ZhangX. (2022). The role of gut-liver axis in gut Microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines10, 524. 10.3390/biomedicines10030524

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  StiglundN.StrandK.CornilletM.StålP.ThorellA.ZimmerC. L.et al (2019). Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front. Immunol.10, 1255. 10.3389/fimmu.2019.01255

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  SuX.GaoY.YangR. (2022). Gut Microbiota-Derived tryptophan metabolites maintain gut and systemic homeostasis. Cells11, 2296. 10.3390/cells11152296

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  SunL.CaiJ.GonzalezF. J. (2021). The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol.18, 335–347. 10.1038/s41575-020-00404-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  ŚwiderskaM.JaroszewiczJ.StawickaA.Parfieniuk-KowerdaA.ChabowskiA.FlisiakR. (2017). The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clin. Exp. Hepatol.3, 127–134. 10.5114/ceh.2017.68466

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  TajiriK.ShimizuY. (2012). Role of NKT cells in the pathogenesis of NAFLD. Int. J. Hepatol.2012, 850836. 10.1155/2012/850836

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  TanG.ZengB.ZhiF.-C. (2015). Regulation of human enteric α-defensins by NOD2 in the Paneth cell lineage. Eur. J. Cell. Biol.94, 60–66. 10.1016/j.ejcb.2014.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  TanY.-Y.YueS.-R.LuA.-P.ZhangL.JiG.LiuB.-C.et al (2022). The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis. Phytomedicine Int. J. Phytother. Phytopharm.103, 154208. 10.1016/j.phymed.2022.154208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  TanY.HuangZ.LiuY.LiX.StalinA.FanX.et al (2023). Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease. J. Ethnopharmacol.310, 116418. 10.1016/j.jep.2023.116418

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  TangW.ZhouJ.YangW.FengY.WuH.MokM. T. S.et al (2022). Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell. Mol. Immunol.19, 834–847. 10.1038/s41423-022-00872-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  ThomasC.GioielloA.NoriegaL.StrehleA.OuryJ.RizzoG.et al (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. Cell. Metab.10, 167–177. 10.1016/j.cmet.2009.08.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  TianB.LiuJ. (2020). Resveratrol: a review of plant sources, synthesis, stability, modification and food application. J. Sci. Food Agric.100, 1392–1404. 10.1002/jsfa.10152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  TianY.MaJ.WangW.ZhangL.XuJ.WangK.et al (2016). Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol. Cell. Biochem.422, 75–84. 10.1007/s11010-016-2807-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  TilgH.AdolphT. E.TraunerM. (2022). Gut-liver axis: pathophysiological concepts and clinical implications. Cell. Metab.34, 1700–1718. 10.1016/j.cmet.2022.09.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  TongC.WuH.GuD.LiY.FanY.ZengJ.et al (2021). Effect of curcumin on the non-alcoholic steatohepatitis via inhibiting the M1 polarization of macrophages. Hum. Exp. Toxicol.40, S310–S317. 10.1177/09603271211038741

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  TongC.LiangY.HanX.ZhangZ.ZhengX.WangS.et al (2023). Research progress of dendritic cell surface receptors and targeting. Biomedicines11, 1673. 10.3390/biomedicines11061673

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  TranS.BabaI.PoupelL.DussaudS.MoreauM.GélineauA.et al (2020). Impaired kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. Immunity53, 627–640.e5. 10.1016/j.immuni.2020.06.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213

  TravassosL. H.GirardinS. E.PhilpottD. J.BlanotD.NahoriM.-A.WertsC.et al (2004). Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep.5, 1000–1006. 10.1038/sj.embor.7400248

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  TrinchieriG. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol.3, 133–146. 10.1038/nri1001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  TripodiA.AnsteeQ. M.SogaardK. K.PrimignaniM.VallaD. C. (2011). Hypercoagulability in cirrhosis: causes and consequences. J. Thromb. Haemost. JTH9, 1713–1723. 10.1111/j.1538-7836.2011.04429.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  VajroP.PaolellaG.FasanoA. (2013). Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr.56, 461–468. 10.1097/MPG.0b013e318284abb5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217

  WachtendorfS.JoninF.OchelA.HeinrichF.WestendorfA. M.TiegsG.et al (2024). The ST2+ Treg/amphiregulin axis protects from immune-mediated hepatitis. Front. Immunol.15, 1351405. 10.3389/fimmu.2024.1351405

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  WagnerC. S.CresswellP. (2012). TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J. Immunol. Balt. Md 1950188, 686–693. 10.4049/jimmunol.1102214

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  WanJ.-Y.WangC.-Z.ZhangQ.-H.LiuZ.MuschM. W.BissonnetteM.et al (2017). Significant difference in active metabolite levels of ginseng in humans consuming Asian or Western diet: the link with enteric microbiota. Biomed. Chromatogr. BMC31, e3851. 10.1002/bmc.3851

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220

  WangY.-D.ChenW.-D.WangM.YuD.FormanB. M.HuangW. (2008). Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatol. Balt. Md48, 1632–1643. 10.1002/hep.22519

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221

  WangL.JiaZ.WangB.ZhangB. (2020a). Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. Turk. J. Gastroenterol. Off. J. Turk. Soc. Gastroenterol.31, 902–909. 10.5152/tjg.2020.19568

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  WangP.WangJ.LiD.KeW.ChenF.HuX. (2020b). Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. J. Nutr. Biochem.81, 108363. 10.1016/j.jnutbio.2020.108363

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  WangH.MehalW.NagyL. E.RotmanY. (2021a). Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell. Mol. Immunol.18, 73–91. 10.1038/s41423-020-00579-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224

  WangR.TangR.LiB.MaX.SchnablB.TilgH. (2021b). Gut microbiome, liver immunology, and liver diseases. Cell. Mol. Immunol.18, 4–17. 10.1038/s41423-020-00592-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225

  WangJ.ZhengD.HuangF.ZhaoA.KuangJ.RenZ.et al (2022). Theabrownin and Poria cocos polysaccharide improve lipid metabolism via modulation of bile acid and Fatty acid metabolism. Front. Pharmacol.13, 875549. 10.3389/fphar.2022.875549

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226

  WangJ.ZhuN.SuX.GaoY.YangR. (2023a). Gut-Microbiota-derived metabolites maintain gut and systemic immune homeostasis. Cells12, 793. 10.3390/cells12050793

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  WangX.HeQ.ZhouC.XuY.LiuD.FujiwaraN.et al (2023b). Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity56, 58–77.e11. 10.1016/j.immuni.2022.11.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228

  WangQ.GuoF.ZhangQ.HuT.JinY.YangY.et al (2024a). Organoids in gastrointestinal diseases: from bench to clinic. MedComm5, e574. 10.1002/mco2.574

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229

  WangQ.LuT.SongP.DongY.DaiC.ZhangW.et al (2024b). Glycyrrhizic acid ameliorates hepatic fibrosis by inhibiting oxidative stress via AKR7A2. Phytomedicine Int. J. Phytother. Phytopharm.133, 155878. 10.1016/j.phymed.2024.155878

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230

  WangX.YueS.-Y.ChenL.ChenJ.LiC.WeiS.-A.et al (2025). Lycium barbarum polysaccharides alleviate experimental autoimmune prostatitis by putrescine/TRAF/JAK/STAT-mediated Th17 differentiation. Phytomedicine147, 157210. 10.1016/j.phymed.2025.157210

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  WeiS.WuX.ChenM.XiangZ.LiX.ZhangJ.et al (2023). Exosomal-miR-129-2-3p derived from fusobacterium nucleatum-infected intestinal epithelial cells promotes experimental colitis through regulating TIMELESS-Mediated cellular senescence pathway. Gut Microbes15, 2240035. 10.1080/19490976.2023.2240035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232

  WeiY.JiangY.LiuM.ZhangX.GuoS.SuS.et al (2025). Chemical structures of lycii fructus polysaccharides tailored the gut microbiota composition of aged Caenorhabditis elegans. Food Hydrocoll.169, 111608. 10.1016/j.foodhyd.2025.111608

  • CrossRef
  • Google Scholar

• 233

  Wieland BrownL. C.PenarandaC.KashyapP. C.WilliamsB. B.ClardyJ.KronenbergM.et al (2013). Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol.11, e1001610. 10.1371/journal.pbio.1001610

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  WongP.PamerE. G. (2003). CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol.21, 29–70. 10.1146/annurev.immunol.21.120601.141114

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235

  WuL.FengJ.LiJ.YuQ.JiJ.WuJ.et al (2021). The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed. Pharmacother. Biomedecine Pharmacother.133, 111036. 10.1016/j.biopha.2020.111036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236

  WuY.DuanZ.QuL.LiuY.MaX.FanD. (2025). Ginsenoside Rk1 ameliorates non-alcoholic fatty liver disease by targeting CD36 to modulate the AMPK signaling pathway. Food Res. Int. ott. Ont.211, 116426. 10.1016/j.foodres.2025.116426

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237

  XiaY.WangY.XiongQ.HeJ.WangH.IslamM.et al (2025). Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC. Hepatol. Balt. Md81, 947–961. 10.1097/HEP.0000000000000762

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238

  XieG.JiangR.WangX.LiuP.ZhaoA.WuY.et al (2021). Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine66, 103290. 10.1016/j.ebiom.2021.103290

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 239

  XuY.HuangX.HuangfuB.HuY.XuJ.GaoR.et al (2023). Sulforaphane ameliorates nonalcoholic fatty liver disease induced by high-fat and high-fructose diet via LPS/TLR4 in the gut-liver axis. Nutrients15, 743. 10.3390/nu15030743

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240

  XuM.XuH.LingY.-W.LiuJ.-J.SongP.FangZ.-Q.et al (2025). Neutrophil extracellular traps-triggered hepatocellular senescence exacerbates lipotoxicity in non-alcoholic steatohepatitis. J. Adv. Res.S2090-1232 (25), 00175–4. 10.1016/j.jare.2025.03.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241

  XueX.WuJ.DingM.GaoF.ZhouF.XuB.et al (2021). Si-wu-tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis. Chin. Med.16, 112. 10.1186/s13020-021-00524-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242

  YanH.-M.XiaM.-F.WangY.ChangX.-X.YaoX.-Z.RaoS.-X.et al (2015). Efficacy of berberine in patients with non-alcoholic fatty liver disease. PloS One10, e0134172. 10.1371/journal.pone.0134172

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243

  Yáñez-MóM.SiljanderP. R.-M.AndreuZ.ZavecA. B.BorràsF. E.BuzasE. I.et al (2015). Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles4, 27066. 10.3402/jev.v4.27066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244

  YangJ.MaX.-J.LiL.WangL.ChenY.-G.LiuJ.et al (2017). Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice. Exp. Ther. Med.14, 4134–4140. 10.3892/etm.2017.5051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245

  YangS.CaoS.LiC.ZhangJ.LiuC.QiuF.et al (2022). Berberrubine, a main metabolite of berberine, alleviates non-alcoholic fatty liver disease via modulating glucose and lipid metabolism and restoring gut microbiota. Front. Pharmacol.13, 913378. 10.3389/fphar.2022.913378

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 246

  YangB.TangG.WangM.NiY.TongJ.HuC.et al (2024). Trimethylamine N-oxide induces non-alcoholic fatty liver disease by activating the PERK. Toxicol. Lett.400, 93–103. 10.1016/j.toxlet.2024.08.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 247

  YangJ.SongB.ZhangF.LiuB.YanJ.WangY.et al (2025a). Curcumin ameliorates hepatic steatosis and insulin resistance through the JNK2/FOXO1/Bcl6 axis and regulate the intestinal flora structure. J. Physiol. Biochem.81, 771–791. 10.1007/s13105-025-01101-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248

  YangX.WangJ.QiX.HouM.LiuM.XiaoY.et al (2025b). HLF and PPARα axis regulates metabolic-associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota. iMeta4, e70022. 10.1002/imt2.70022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249

  YeH.MaS.QiuZ.HuangS.DengG.LiY.et al (2022). Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. J. Ethnopharmacol.296, 115457. 10.1016/j.jep.2022.115457

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 250

  YinY.SichlerA.EckerJ.LaschingerM.LiebischG.HöringM.et al (2023). Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis. J. Hepatol.78, 820–835. 10.1016/j.jhep.2022.12.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251

  YingH.-Z.LiuY.-H.YuB.WangZ.-Y.ZangJ.-N.YuC.-H. (2013). Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc.52, 53–60. 10.1016/j.fct.2012.10.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 252

  YuB.QinS.-Y.HuB.-L.QinQ.-Y.JiangH.-X.LuoW. (2019). Resveratrol improves CCL4-induced liver fibrosis in mouse by upregulating endogenous IL-10 to reprogramme macrophages phenotype from M(LPS) to M(IL-4). Biomed. Pharmacother. Biomedecine Pharmacother.117, 109110. 10.1016/j.biopha.2019.109110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 253

  ZangS.WangL.MaX.ZhuG.ZhuangZ.XunY.et al (2015). Neutrophils play a crucial role in the early stage of nonalcoholic steatohepatitis via neutrophil elastase in mice. Cell. biochem. Biophys.73, 479–487. 10.1007/s12013-015-0682-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 254

  ZhangM.ZhangS. (2020). T cells in fibrosis and fibrotic diseases. Front. Immunol.11, 1142. 10.3389/fimmu.2020.01142

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 255

  ZhangZ.ZhangC. (2025). Regulation of cGAS–STING signalling and its diversity of cellular outcomes. Nat. Rev. Immunol.25, 425–444. 10.1038/s41577-024-01112-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 256

  ZhangJ.PingJ.JiangN.XuL. (2022). Resveratrol inhibits hepatic stellate cell activation by regulating autophagy and apoptosis through the SIRT1 and JNK signaling pathways. J. Food Biochem.46, e14463. 10.1111/jfbc.14463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 257

  ZhangX.SharmaP.MaschmeyerP.HuY.LouM.KimJ.et al (2023). GARP on hepatic stellate cells is essential for the development of liver fibrosis. J. Hepatol.79, 1214–1225. 10.1016/j.jhep.2023.05.043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 258

  ZhangF.JiangQ.CaiJ.MengF.TangW.LiuZ.et al (2024a). Activation of NOD1 on tumor-associated macrophages augments CD8+ T cell-mediated antitumor immunity in hepatocellular carcinoma. Sci. Adv.10, eadp8266. 10.1126/sciadv.adp8266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 259

  ZhangJ.QiH.LiM.WangZ.JiaX.SunT.et al (2024b). Diet mediate the impact of host habitat on gut microbiome and influence clinical indexes by modulating gut microbes and serum metabolites. Adv. Sci. Weinh. Baden-Wurtt. Ger.11, e2310068. 10.1002/advs.202310068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 260

  ZhangZ.ZhiY.WangS.ZhangF.ZhangS.WuJ. (2025). Zexie Tang Polysaccharides (ZXTPs) alleviate high-fat diet-induced NAFL in mice through improving intestinal microbiota imbalance and liver metabolic dysfunction. Carbohydr. Polym.367, 123937. 10.1016/j.carbpol.2025.123937

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 261

  ZhaoX.YangL.ChangN.HouL.ZhouX.YangL.et al (2020). Neutrophils undergo switch of apoptosis to NETosis during murine fatty liver injury via S1P receptor 2 signaling. Cell. Death Dis.11, 379. 10.1038/s41419-020-2582-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 262

  ZhaoM.GuanZ.TangN.ChengY. (2023). The differences between the water- and alkaline-soluble Poria cocos polysaccharide: a review. Int. J. Biol. Macromol.235, 123925. 10.1016/j.ijbiomac.2023.123925

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 263

  ZhiN.ChangX.ZhaL.ZhangK.WangJ.GuiS. (2025). Platycodonis radix polysaccharides suppress progression of high-fat-induced obesity through modulation of intestinal microbiota and metabolites. Phytomedicine Int. J. Phytother. Phytopharm.142, 156653. 10.1016/j.phymed.2025.156653

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 264

  ZhongT.ZhangW.GuoH.PanX.ChenX.HeQ.et al (2022). The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies. Acta Pharm. Sin. B12, 1761–1780. 10.1016/j.apsb.2021.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 265

  ZhouD.PanQ.LiuX.-L.YangR.-X.ChenY.-W.LiuC.et al (2017). Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J. Gastroenterol. Hepatol.32, 1640–1648. 10.1111/jgh.13742

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 266

  ZhouD.ChenY.-W.ZhaoZ.-H.YangR.-X.XinF.-Z.LiuX.-L.et al (2018). Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp. Mol. Med.50, 1–12. 10.1038/s12276-018-0183-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 267

  ZhuW.YanM.CaoH.ZhouJ.XuZ. (2022). Effects of Clostridium butyricum capsules combined with Rosuvastatin on intestinal flora, lipid metabolism, liver function and inflammation in NAFLD patients. Cell. Mol. Biol. noisy--gd. Fr.68, 64–69. 10.14715/cmb/2022.68.2.10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 268

  ZhuL.-R.LiS.-S.ZhengW.-Q.NiW.-J.CaiM.LiuH.-P. (2023). Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front. Immunol.14, 1086078. 10.3389/fimmu.2023.1086078

  • Pubmed Abstract
  • CrossRef
  • Google Scholar